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The goal of this research was to determine the effect of different doses of
galactooligosaccharide (GOS) on the fecal microbiota of healthy adults, with a
focus on bifidobacteria. The study was designed as a single-blinded study, with
eighteen subjects consuming GOS-containing chocolate chews at four increasing
dosage levels; 0, 2.5, 5.0, and 10.0 g. Subjects consumed each dose for 3
weeks, with a two-week baseline period preceding the study and a two-week
washout period at the end.

Cultural methods were used for bifidobacteria,

Bacteroides, enterobacteria, enterococci, lactobacilli, and total anaerobes;
culture-independent methods included denaturing gradient gel electrophoresis
(DGGE) and quantitative real-time PCR (qRT-PCR) using Bifidobacteriumspecific primers.

All three methods revealed an increase in bifidobacteria

populations, as the GOS dosage increased to 5 or 10 g.

Enumeration of

bifidobacteria by qRT-PCR showed a high inter-subject variation in bifidogenic
effect and indicated a subset of 9 GOS responders among the eighteen subjects.
There were no differences, however, in the initial levels of bifidobacteria between

the responding individuals and the non-responding individuals. In order to gain a
community wide perspective of the impact of GOS on the fecal microbiota of the
subjects, we then performed high throughput multiplex community sequencing of
16S rRNA tags. Multiplex sequencing of the 16s rRNA tags revealed that GOS
induced significant compositional alterations in the fecal microbial populations by
increasing the phyla Actinobacteria.

The population shifts caused by

consumption of 10 g of GOS were numerically substantial, leading for example,
to a ten-fold increase in bifidobacteria in four subjects, enriching them to 18-33%
off the fecal microbial community, and a five-fold increase in seven additional
subjects.

This increase in bifidobacteria abundance was generally at the

expense of only one group of bacteria, namely the genus Bacteroides.
Collectively, this study showed that a high purity GOS, administered in a
confection product at doses of 5 g or higher, was bifidogenic, while a dose of 2.5
gram showed no significant effect. Our results also demonstrated that GOS is
remarkable for its ability to enrich specifically for bifidobacteria in human fecal
samples.
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Preface
This thesis is composed of four chapters. Chapter 1 provides a review of
the current literature on the effects of prebiotics on the human intestinal
microbiota, with a special focus on galactooligosaccharides (GOS). Chapter 2
describes our published (Davis et al., 2010 Int. J. Food Microbiol. In press)
results focusing on the impact that consecutive doses of the prebiotic
galactooligosaccharides have on the intestinal microbiota of healthy adults.
Chapter 3 describes additional results from that study, where we focus on
community sequencing and the highly specific bifidogenic response GOS has on
the human gastrointestinal tract. Finally, Chapter 4 provides a conclusion section
that summarizes the major research findings presented within this thesis and the
suggested areas for future research.
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Chapter 1
Prebiotic Activity of Galactooligosaccharides:
A Review of structure, function, and in vivo human studies

2
Introduction
Consumers have become increasingly aware of the importance of the
human gastrointestinal microbiota in promoting health and well-being (48, 55).
However, because the human intestine is a complex ecosystem in which
thousands of different bacterial species reside, defining the microbial composition
and establishing the function of this ecosystem represent a considerable
challenge. Nonetheless, there is now substantial interest in understanding the
role of the colonic microbiota and developing the means to manipulate the
composition of the intestinal microbiota to enhance human health (30). In
particular, the role of diet has been the subject of much of this interest, due to the
potential impact specific dietary substances may have on the intestinal
environment.
Without doubt, the group of dietary substances that have received the
most attention for their ability to modulate the colonic microbiota are the
prebiotics. Prebiotics are defined as a “a selectively fermented ingredient that
allows specific changes, both in the composition and/or activity in the
gastrointestinal microbiota that confers benefits upon host welling-being and
health” (52). Most of the compounds currently recognized as prebiotics are
carbohydrates, either polysaccharides or oligosaccharides. Although many
carbohydrates have been suggested to have prebiotic activity (31), the most wellstudied include the fructans, inulin, and fructooligosaccharides (FOS), and the
galactooligosccharides (GOS). The latter are of particular interest due to their
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similarity to human milk oligosaccharides. Moreover, the ability of GOS to enrich
for bifidobacteria and/or lactobacilli in the human intestinal tract is now wellestablished. However, many questions remain regarding the amount of GOS
necessary to generate bifidogenic (or lactobacilligenic) changes in the human
intestinal tract, the means of delivery and stability of GOS in foods, and the effect
of GOS on the overall composition of the microbiota.
In this review, the classification, structure, and means of production of
prebiotics, and GOS in particular, will be described. An overview of intestinal
microbial ecology will also be described, including how prebiotics and GOS
influence the microbiota. Finally, published results using GOS in human feeding
trials, including studies with infants, healthy adults, and elderly adults will be
reviewed.

Classification and Properties of Prebiotics
The recent commercialization of non-digestible oligosaccharides as food
ingredients has triggered a vast amount of research on their potential role in
colonic health.

Since these non-digestible oligosaccharides are not hydrolyzed

by enzymes in the human small intestine, they reach the colon almost intact, and
have coined the name “prebiotics” (3). Prebiotics were first defined as a „nondigestible food ingredient that beneficially affects the host by selectively
stimulating the growth and/or activity of one or a limited number of bacteria in the
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colon, and thus improves host health‟ (30). This prebiotic definition has since
then been revised to „a selectively fermented ingredient that allows specific
changes, both in the composition and/or activity in the gastrointestinal microbiota
that confers benefits upon host welling-being and health‟ (53). Many food
oligosaccharides and polysaccharides have claimed to provide prebiotic activity
(including dietary fiber), however, not all dietary carbohydrates are considered
prebiotics. Those classified as prebiotics are short-chain oligosaccharides and
the degree of polymerization of these oligosaccharides varies from 2 to 60. (16,
64; Table 1). Based on this and other potential claims to follow, there is a need
to establish clear criteria for classifying a prebiotic. These classifications require
that the ingredient demonstrates (i) resistance to hydrolysis and absorption in the
upper part of the gastrointestinal tract; (ii) serve as a selective substrate for
fermentation by one or a limited number of potentially beneficial bacteria in the
colon, resulting in an increase in their growth and/or metabolic activity; (iii) alter
the composition of the colonic microflora toward a healthier composition, and (iv)
encourage effects that are beneficial to the host‟s health(24, 30, 70, 71). While
the research on prebiotics is continuing to surge, most of the studies involving
prebiotic oligosaccharides have been carried out using inulin and its
fructooligosaccharide (FOS) derivatives, together with various forms of
galactooligosaccharides (GOS). Specifically, inulin and FOS have been studied
intensively in vivo over the past decade, while the studies associated with GOS
are still young but hold potentially promising data for the prebiotic field.
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Table 1. Carbohydrates used as prebiotics1
Fructooligosaccharides (FOS)
Galactooligosaccharides (GOS)
Gentiooligosaccharides
Inulin
Isomaltooligosaccharides
Lactulose
Lactosucrose
Soybean oligosaccharides
Xylooligosaccharides
__________________________________
1
Adapted from (67, 68)

Galactooligosaccharides (GOS)
Human Milk Oligosaccharides – GOS. For the first few months of life, human
milk is often the sole dietary source. Not only does it contain all the nutrients
necessary for infants to thrive, but also nutrients that may provide health benefits
beyond those of traditional nutrients, such as GOS. Human milk is considered
one of the earliest sources of GOS with approximately 7% carbohydrates, 90% of
which is lactose, and a variety of oligosaccharides based on lactose (21, 57).
Oligosaccharides, after lactose and lipids, make up the third largest component
in human milk (61), and are found at their highest levels in colostrum, where they
can reach up to 24% of the total colostrum carbohydrates. In the first two months
after birth, the concentrations of these oligosaccharides steadily decrease to
between 19% and 15% (57). Human milk oligosaccharides, once ingested, can
withstand the low pH in the gut (32) and resist degradation through enzymes
from the pancreas and brush border membrane (20, 32). Once these human
milk oligosaccharides reach the gastrointestinal tract, they have been shown to
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establish a microbiota predominant in lactobacilli and bifidobacteria (45), which
differs from that of infants fed on cow‟s milk (37, 51). Oligosaccharides in milk
can reach as high as 8-12 g l-1 (46, 47), which is 100 times greater than in cow‟s
milk. The ability of breast-fed infants to utilize oligosaccharides in breast milk,
including GOS which infants cannot digest in the upper gut, is thought to be the
reason for the predominance of bifidobacteria within the gastrointestinal
microflora (20, 37, 62). When human milk is not available for various reasons,
incorporation of manufactured prebiotics such as GOS can be a useful addition
to formulas so that functional characteristics associated with breast milk can be
replicated, such as its bifidogenic effects (52). A mixture can be developed for
formula that is based on the analysis of human milk and the high concentration of
galactose. These formulas can later be fed to infants to obtain comparisons of
gut microbiota and fecal fermentation product composition to determine the
closeness of relation to that of breast-fed infants (see later).
Composition and properties of GOS. There are three main methods by which
prebiotic oligosaccharides are produced: (i) plant extraction of natural
oligosaccharides, (ii) monitored hydrolysis of natural polysaccharides, and (iii)
using hydrolases and/or glycosyl transferases from microbial or plant sources for
enzymatic synthesis (34, 49). The final structure composition of the prebiotic is
dependent on the method in which the prebiotic is produced. Linkages that are
recalcitrant to hydrolysis by human or microbial hydrolases, such as β-glycosidic
linkages, are generally found in all prebiotics (72). GOS are produced from
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lactose through the action of β-galactosidases, and, depending on the source of
the β-galactosidase, different synthetic product mixtures are formed (19). In
general, β-galactosidase is known as an enzyme that is able to catalyze the
hydrolysis of lactose, while also being able to catalyze the transgalactosylation
reaction needed to develop the GOS product (28, 65). It is thought that
increased specificity of GOS can be obtained by using β-GOS, which is
synthesized by bifidobacteria, utilizing their own β-galactosidase in the
manufacturing of the product. GOS consists of chains of galactose molecules
ending in a terminal glucose molecule, with a degree of polymerization (DP) from
between 2 to 10 and various types of linkages. Production of GOS for
commercial products utilizes whey-derived lactose as the main raw material (4,
102), however GOS can be produced from lactose in cow‟s milk. Since whey is
produced in large amounts by the dairy industry as a by-product of cheese
making, it becomes a more efficient way of reducing waste (52). When in syrup
form, GOS is usually transparent and more viscous than high-fructose corn
syrups (HFCS). When compared to sucrose, GOS has about one third of the
sweetness (63), and shows a good moisture retention and high solubility (52).

Figure 1. Synthesis of galactooligosaccharides from lactose refined from whey1.
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1

Adapted from (52)

GOS Stability in Foods. As effective functional food ingredients, prebiotics
must be chemically stable to food processing conditions. Many processing
treatments involve low pH or heat, such as yogurt fermentation or pasteurization,
which may hydrolyze the prebiotics to their respective monosaccharides. In
addition, some prebiotic structures consist of reducing ends, which through
Maillard reactions may interact with amino acids present in proteins.
Hydrolyzation of prebiotics would not allow them to retain prebiotic activity in
vivo, due to the released monosaccharides being absorbed in the intestinal tract.
This would allow the prebiotics to be utilized by the general commensal
microflora, instead of selecting for beneficial intestinal and/or prebiotic bacteria in
the colon. Maillard reactions may also reduce the prebiotic activity and make
them no longer available for metabolism by beneficial bacteria. The chemical
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stability of GOS was reported in a study performed by Sako et al (1999). Using
aqueous buffered solutions of Oligomate 55, stability was observed at 100˚C and
pH 2, 120˚C and pH3, and at 160˚C and neutral pH. When compared to sucrose
at 10% concentration, GOS was found to be about three times more stable, as
sucrose was degraded under many of the conditions tested. GOS was also
found to be stable when tested in acidic conditions during long-term storage at
room temperature. Due to their stability, GOS can be incorporated into a wide
variety of foods (in some cases coupled with FOS) and are currently used in
commercial commodities including infant formulas, dairy products, sauces,
soups, breakfast cereals, beverages, snack bars, ice creams, bakery products,
animal feeds, and as sugar replacements (103).
Health benefits linked to GOS. The human gastrointestinal tract, especially the
colon, is a somewhat recently explored microbial ecosystem, offering a good
opportunity for the development of dietary interventions targeting disease
reduction risk and maintenance of good health. Since GOS has been shown to
be fermented by the colonic bacterial flora, in particular bifidobacteria, studies
investigating the potential bifidogenic relationship are ever growing. The
bifidobacteria population is not only important for the eco-physiology of the
colonic microbiota; they are also believed to have health benefits. Evidence has
shown that bifidobacteria are the main species colonizing the infant
gastrointestinal microbiota, which in turn has decreased the overall numbers of
potentially pathogenic bacteria. However, with age, the number of bifidobacteria
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begins to decrease and is slowly replaced by bacteria mainly associated within
the phylum Firmicutes or Bacteroidetes. Due to this decrease, efforts to restore
or increase this population through the use of prebiotics, especially GOS, has
become of great interest. These organisms have been linked to increased
resistance to infection and diarrheal disease (33, 74, 93, 101), stimulation of
immune system activity (44, 77), as well as protection against cancer (69, 78). In
animal models, some bifidobacteria manifest strong anti-mutagenic and antitumor properties that have prophylactic and therapeutic benefits (39). Along with
potential immune benefits, GOS has been studied as a potential therapeutic
agent for IBS and IBD patients, by fermenting and increasing bifidobacteria that
demonstrate pro-inflammatory like benefits and improve abdominal symptoms
(82). GOS has also been linked to potential laxative-like properties within elderly
by relieving constipation, however, responses differ individually (89). Small
human trials, with mixed effects, involving GOS and the potential to stimulate true
calcium absorption in postmenopausal women have also been performed. An
increase in calcium absorption in postmenopausal women was observed,
however further research is required for any definitive conclusions to be drawn
(97). GOS has been under investigation in the area of cardiovascular effects as
well, and very few trials have used it as a prebiotic. In a study performed by van
Dokkum and colleagues (1999), GOS did not seem to alter blood lipid
concentration and glucose absorption; however it should not be excluded for
people with elevated blood lipid concentration or diabetic patients, where it
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potentially could be beneficial. Another area of interest, with respect to prebiotic
benefits, is allergic disorders. The prevalence of allergic disorders in developed
countries has been on a steady increase over the last few decades. A delayed
maturation of the immune system has been associated with a higher risk of
allergies in children, and it has been suggested that breast feeding reduces this
incidence. Since breast feeding is associated with high levels of GOS,
supplementation of GOS has been shown to induce a beneficial antibody profile
in infants at risk for allergy, while leaving the response to vaccination intact (99).
Given that positive results have arisen from animal studies, it is important
that systematic studies are continually instigated to test for continued GOS
benefits in humans. Researchers are probably just beginning to touch the full
potential of health benefits conferred by GOS and so far, the majority of
investigations have focused on more obvious gastrointestinal-related diseases.
Other areas of health, however, will undoubtedly expand on these potential
benefits in the future.
The Human Intestinal Microbiota
This predominantly anaerobic microbiota is able to salvage energy for the
host by fermenting undigested carbohydrates and proteins to short-chain fatty
acids, which are then absorbed (15). The intestinal microbiota may also
synthesize vitamins (18), protect against invasive species that are often
pathogenic (10, 26), and possibly contribute to the economy of essential amino
acids in humans (85, 94).
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Breakdown of polysaccharides in the large intestine is a complex process
involving various enzymes (poly-, oligo- and monosaccharidases) from many
different species, and cross-feeding by the microflora (15). Evidently the effect of
such a process on the growth of specific bacteria is difficult to predict in an
ecosystem consisting of such a large number of physiologically and nutritionally
diverse bacterial species. Not all intestinal bacteria are beneficial to health, and
a long-established concept is that of beneficial and possibly harmful species.
Generally beneficial genera include Bifidobacterium and Lactobacillus, both of
which are saccharolytic, whereas some species such as Clostridium perfringes
and Escherichia coli can be considered harmful (29, 86). The human intestinal
microbiota is affected by many factors such as age, drug therapy, disease, diet,
host physiology, peristalsis, local immunity, and in situ bacterial metabolism (9).
However, diet is probably the most significant factor determining the type of
gastrointestinal microflora that develops since foodstuffs provide the main
nutrient sources for colonic bacteria.
GOS Human feeding trials
Infants and pregnant mothers. Born with an essentially sterile gastrointestinal
tract, infants provide a unique opportunity to investigate the effects of prebiotics
on the gastrointestinal microbiota. Immediately after birth, the colonization of the
infant gastrointestinal tract starts (73) and is influenced by the mode of delivery
(8, 35), the composition of the maternal microbiota (87), and the mode of feeding
– ie, breast milk or infant formula (37, 84). Over a series of weeks and months,
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infants become progressively colonized by different bacteria, which results in the
establishment of an increasingly complex and stable microbiota. Since the
development of the gastrointestinal microbiota is profoundly influenced by the
feeding regimen, those infants fed breast milk typically stimulate bifidobacteria to
become dominant in the first few days of life (1, 53). This dominance of
bifidobacteria in the gastrointestinal microbiota of breast-fed infants (90-95% of
total microbiota) can continue up through the first two years of an infant‟s life, and
is fundamental for the well-being of the infant (13, 22, 92). As discussed earlier,
the explanation for this dominance of bifidobacteria in breast-fed infants is
thought to occur due to the natural oligosaccharides, so called prebiotic factors,
found in human milk. Promoting this early gastrointestinal colonization with
beneficial flora is thus important in infants, especially when breast milk is not
available for various reasons. Due to their complexity, oligosaccharides with
structures identical to human milk are not yet available as dietary ingredients;
however prebiotics similar to human milk oligosaccharides have proved
promising. The development of improved infant formulas that emulate the
beneficial effects of human milk by supplementing specific prebiotics that
selectively stimulate beneficial indigenous bacteria such as bifidobacteria, has
gained considerable interest.
Infant and neonate studies are probably the area most extensively
researched using GOS as a prebiotic supplement for infant formulas. The
majority of the trials, listed in Table 2, have focused on demonstrating the

Table 2. Infant and pregnant mother studies with the prebiotic galactooligosaccharide (GOS)

Type

Dose

Subjects
Neonates
≤ 37 weeks

No

Length
of study

Objectives

Result

Reference

14-33 days

Efficacy and safety of
GOS supplementation
in reducing the incidence
of sepsis and improving
physical growth

No significant difference
in weight, higher
bifidobacteria colony
counts, lower pathogenic
bacteria colony counts

Srinivasjois
et al. (2009)

n=215

first 26 weeks

Explore the effect of
infant milk formula (IMF)
during the first 26 weeks

No significant differences
seen in white blood count,
lymphocyte numbers, or
immunoglobulins

Raes
et a(2009)

Randomized
Control Trials
(RCT)

_

Double-blind
randomized
controlled trial
(DBRCT)

scGOS/lcFOS
(9:1) 6 g/d

Double-blind
randomized

scGOS/lcFOS
Breast fed
(9:1) 6 g/d,
and formula
6.0E10 Bifidobacterium fed infants
animalis viable cells

n=63; 57

4 months

Determine if prebiotics or
probiotics should be used
to reach a gut flora
dominant by bifidobacteria

Prebiotic fed infants tend to Bakker-Zierikzee
have a higher percentage of et al. (2005)
bifidobacteria counts compared
to those of prebiotic fed infants

DBRCT,
Parallel group

scGOS/lcFOS
(9:1) 4 g/L plus
3 different prebiotic
combinations

Formula fed
term infants

n=284

52 weeks

Evaluate infant formulas
containing probiotics and
synbiotics for safety and
tolerance

Incidence of diarrhea
significantly lower in
prebiotic group, stool
frequency significantly
higher with synbiotics

DBRCT

5 g/L GOS, control

Formula fed
term infants

n=159

12 weeks

Determine bifidogenic
effects of GOS in a followon formula

At weeks 6 and 12 a
Fanaro
higher median number
et al. (2008)
of bifidobacteria was observed
in the GOS vs. control group

DBRCT

scGOS/lcFOS
(9:1) 8 g/L, control

Hypoallergenic
formula fed
term infants

n=84

6 months

Analyze the effect of
GOS/FOS on the immune
response in infants

Significant reduction in
plasma level of total
IgE, IgG1, IgG2, and
IgG3

van Hoffen
et al. (2009)

Randomized
controlled study

0.24 g/100mL

Formula fed
term infants

n=164

3 months

Investigate the effect of
infant formula supplemented
with low levels of GOS on
intestinal micro-flora and
fermentation characteristics

Intestinal bifidobacteria,
lactobacilli, acetic acid,
and stool frequency were
significantly increased.
stool pH decreased

Ben
et al. (2008)

Double-blind
controlled

4 g/L GOS,
Other prebiotics

Formula fed
term infants

n=117

28 days

Investigate effects of
prebiotic blends on fecal
bacterial populations

No significant changes
in bacterial populations
for GOS or other blends

Nakamura
et al. (2009)

Healthy term
infants

4 trials
(n=126)

Chouraqui
et al. (2008)
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Table 2. Continued

Type
DBRCT

Subjects

No

Length
of study

scGOS/lcFOS
(8:2) increasing
dose (max=1.25 g/kg)

Preterm
infants

n=113

GOS/lcFOS
(9:1) 3 g; 3 times
a day (9 g/d)

Pregnant
women
vaginal delivery

n=48

Dose

Objectives

Result

Reference

30 days

Determine the effect of
enteral supplementation
of prebiotic mixtures on
serious infectious morbidity

No significant reduction
of serious endogenous
infection but trend toward
lower incidence

Westerbeek
et al. (2010)

week 25-delivery

Determine how
supplementation with GOS
and lcFOS in the last
trimester of pregnancy affects
maternal and neonatal gut
microbiota

GOS/lcFOS exhibits a
bifidogenic effect on
maternal gut microbiota
but does not transfer to
neonates

Shadid
et al. (2007)

Pregnant Mothers:
DRBCT
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abilities of GOS to increase fecal bifidobacteria populations. However, a study
done by the Nakamua group (2009) did not see any significant differences in
change of bacterial populations, but stated the age related differences involved in
this study indicated that the GOS blends may have a greater impact on younger
infants. With an increase in the fecal bifidobacteria populations, studies
performed by Bakker-Zierikzee et al. (2005), Xiao-Ming et al. (2008), and
Srinivasjois et al (2009) also exhibited a decrease in fecal pH with more frequent,
softer stools. Srinivasjois et al (2009) found that the decrease in fecal pH
restricts the growth of potential pathogens, which mimics the pH of breast-fed
infants. In addition to the bifidogenic effects, it has been suggested that breast
feeding reduces the incidence of allergic disorders in children, in particular atopic
dermatitis and wheezing (25). When the effect of GOS/FOS on the immune
response in infants was analyzed by E. van Hoffen and colleagues (2009), a
significant reduction in the total Ig response was observed. In addition, the
GOS/FOS ratio (9:1) modulated the immune response toward cow’s milk protein
(CMP), leaving the response to vaccination intact. Raes et al (2009) further
explored the effects that GOS has on the basal immune parameters during the
first 26 weeks of life and found that there was no change when compared to the
developing immune system in healthy breast-fed infants. Several of the studies
also observed that GOS did not affect weight gain, crying, regurgitation, and
vomiting (Table 2). A study done by Shadid and colleagues (2007) also explored
how supplementation with GOS in the last trimester of pregnancy affected
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maternal and neonatal gastrointestinal microbiota. They found that the
supplementation had a bifidogenic effect on the maternal gastrointestinal
microbiota that is not directly transferred to the neonates. Results suggested
however, that maternal microbiota plays a role in the initial colonization of the
infant gastrointestinal tract during the first days of life, as assessed by the high
similarity index (SI; 60%). The continued research on infants shows that the
incorporation of manufactured prebiotics such as GOS can be a useful addition
to formula feeds in order to replicate some of the functional attributes associated
with breast milk, particularly its bifidogenic effects; especially with breast milk is
not available.
Healthy adults. Since gastrointestinal health can be controlled artificially
(introduction of prebiotics), the diet might be the most important regulating factor.
As infants, the number of bifidobacteria is the dominant bacterial group, even for
bottle-fed infants now that supplementation of prebiotics has been explored.
After solid food introduction and weaning from formula or breast milk, the number
of bifidobacteria decrease dramatically as bacteroides and firmicute groups
become dominant with advanced aging. Due to the beneficial effects that
bifidobacteria exert on their host, as discussed earlier, efforts to increase
bifidobacteria populations in adult humans are rapidly growing. Introduction of
functional foods, in particular prebiotics, has taken the attention of diet
supplementation to a more advanced level beyond human milk oligosaccharides.
Studies are no longer just focusing on effects in infants, but rather are turning
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their attention to the bifidogenic effects seen in adults, and the possible
correlation that exists between increased bifidobacteria and health.
Several studies involving healthy human adults have been performed to
determine the effects that GOS has on the gastrointestinal microbiota (Table 3).
Studies performed by Ito et al (1990; 1993), Alles et al (1999), Depeint et al
(2008), Davis et al (2010), and Alander et al (2001) showed that GOS greatly
increased bifidobacteria populations and in some cases exhibited a linear-like
relationship between the amount of GOS and the number of bifidobacteria in the
feces. Effects of GOS on blood lipid concentrations, glucose absorption, and
calcium and nonheme-iron absorption were also studied in humans. W van
Dokkum and colleagues (1999) showed that 15g of GOS was well tolerated with
subjects however, beyond increased flatulence the GOS effects were limited.
They observed not cholesterol lowering effects and there was no alteration in
blood lipid concentration or glucose absorption. Similar results were observed by
van den Heuvel and colleagues (1998), as they did not observe any affect on iron
or calcium absorption with the consumption of 15g/day of GOS. An additional
study by van den Heuvel et al (2000) explored the effects of GOS on calcium
absorption in postmenopausal women and observed an increase in calcium
absorption by 16% however, this was not accompanied by increased urinary
calcium excretion. This observation implies that GOS may indirectly increase
calcium uptake by the bones and/or inhibit bone resorption in postmenopausal
women. Research done by Davis et al (2010) showed that a bifidogenic dose

Table 3. Healthy adult studies with the prebiotic galactooligosaccharide (GOS)

Type

Dose

Subjects

No

Length
of study

Objectives

Result

Reference

Latin square
randomized
double-blind
diet controlled

3 treatments of
inulin, FOS, and
GOS (15 g/d)

Healthy Men

n=12

12 weeks

Study effect of 15 g/d
nondigestible
oligosaccharides

For GOS; significantly
higher fecal wet weight,
acetic acid. Significantly
lower fecal dry weight.
Increase in flatulence

van Dokkum
et al. (1999)

Double-blind
randomized
cross-over study

20 g/d TOS

Postmenopausal
women

n=12

37 days

Investigate whether
TOS stimulates true
Ca absorption in
postmenopausal
women with decreased
efficiency of Ca absorption

Increased Ca absorption
observed due soley to TOS

van den Heuvel
et al. (2000)

Randomized
cross-over study

3 treatments of
inulin, FOS, and
GOS (15 g/d)

Nonanemic
men

n=12

12 weeks

Effects of nondigestible
oligosaccharides on
metabolism/absorption of
calcium or iron in humans

No significant differences
van den Heuvel
were observed with respect et al. (1998)
to iron or Ca absorption in any
of the treatments

Single-blind
cross-over study

52% GOS
0, 2.5, 5, or 10 g/d

Healthy adults

n=12

7 weeks

Effects of GOS on microflora,
stool weight, abdominal
tolerance, and laxative
similarities

Linear relationship between Ito et al (1990)
amount of GOS and increase
in bifidobacteria. Lactobacilli
slightly increased with dose

Single-blind
randomized

93% GOS
0, 2.5, 5, or 10 g/d

Healthy adults

n=18

16 weeks

Determine the effect of
different doses of GOS on
the fecal microbiota of
healthy adults with a focus
on bifidobacteria

Significant increase of
bifidobacteria was seen
after 5.0 g/d in 50% of the
subjects.

Davis
et al. (2010)

Double-blind
randomized
cross-over study

15 g/d GOS

Japanese
men

n=12

6 days

Effects of GOS after
ingestion on the human
microflora and metabolism

Bifidobacteria and
Lactobacilli significantly
increased. Bacteroides
and Canidida significantly
decreased. Bifidobacteria
percentage of total bacteria
increased.

Ito et al. (1993)

Parallel
single-blind

7.5 g/d or 15 g/d

Healthy adults

n=18 (W) 3 weeks
n=22 (M)

Compare the effect of
two doses of GOS on the
gut microbiota composition

Increase in bifidobacteria
Alles et al. (1999)
was seen but not significant.
No other significant changes
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Table 3. Continued

Type

Dose

Subjects

No

Length
of study

Objectives

Result

Reference

Randomized
parallel-design

GOS/probiotic mix
3.8 g/d GOS to mix

Healthy adults
Male wistar rats

n=38
n=40

8 weeks

Investigate the effects of
prebiotic supplementation
on a probiotic bacteria mix

There was not significant
Tiihonen
effect with the rats on
et al. (2008)
bacteria population. Increase
in bifidobacteria numbers
observed in humans but not
significant

Double-blind
cross-over study

2.5 g/d of GOS
or FOS

Healthy adults

n=15

15 weeks

Determine the effect of
GOS containing biscuits
on the composition and
activity of the fecal
microflora

Increased metabolic activity Tannock
but not necessarily
et al. (2004)
increased bifidobacteria
numbers. Increased staining
in Bifidobacterium adolescentis

Randomized
Single blinded study

8.1 g/d GOS
with B. lactis Bb-12

Healthy adults

n=30

6 weeks

Further develop the PCRELISA methods to follow
fluctuations in bifidobacteria

Changes detected were not
consistent

Randomized
Single blinded study

8.1 g/d GOS
with B. lactis Bb-12

Healthy adults

n=30

6 weeks

Investigate the effect of
GOS and/or the probiotic
strain on composition of
indigenous bifidobacteria
populations using PCRDGGE

5 adults showed changes
Satokari
in the DGGE profile of
et al. (2001)
bifidobacteria. The prebiotic
did not prolong the persistence
of the probiotic strain

Randomized
Single blinded study

8.1 g/d GOS
with B. lactis Bb-12

Healthy adults

n=30

6 weeks

Effect of GOS-containing
syrup on colonization and
persistence of B. lactis
Bb-12 in the gastrointestinal
tract

Mean numbers of
bifidobacteria increased
slightly in all subjects.
Probiotic strain was not
enhanced for survival or
persistence by GOS

Alander
et al. (2001)

Double-blind
randomized
cross-over study

0.0, 3.6, and 7.0 g/d
GOS from B. bifidum
7.0 g/d industrial GOS

Healthy adults

n=59

4 weeks

Access prebiotic potential
of GOS produced through
β-galactosidases from the
probiotic B.bifidum against
industrial GOS

Probiotic GOS
significantly increased
bifidobacteria numbers
after 7.0 g/d. Significant
relation to bifidobacteria
proportion and probiotic
GOS dose observed

Depeint
et al. (2008)

Malinen
et al. (2002)
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Table 3. Continued

Type

Dose

Subjects

No

Length
of study

Objectives

Result

Reference

DBRCT

10 g/d of GOS powder

Healthy adults

n=8

21 days

Assess tolerance of
GOS and the effect that
10 g/d administration has
on fecal concentrations of
bacteria

Bifidobacteria concentration
was significantly higher
after day 7, 14, 21
compared to day 1. Breath
H2 was significantly lower
on day 7, 14, 21 compared
to day 1

Bouhnik
et al. (1997)

DBRCT
Parallel study

7 non-digestible
carbohydrates (NDCH)
Including GOS
2.5, 5.0, 7.5, or 10 g/d

Healthy adults

n=200

5 weeks

Determine the bifidogenic
potential of different NDCH
used in human diets and
determine a dose response

GOS was found to be
bifidogenic. A linear
dose relationship
was found

Bouhnik
et al. (2004)

DBRCT

15 g/d GOS

Healthy adults

n=12

2 weeks

Determine fecal frequency
and gastrointestinal
symptoms associated with
ingestion of GOS containing
yogurt

Defecation frequency
and flatulence increased
Fecal bifidobacteria did not
show an increase

Teuri et al. (1998)
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dependent response occurred in half of the subjects, indicating a possible
‘responders’ effect in healthy adults. This ‘responders’ and ‘non-responders’
theory can be explained by the presence or absence of specific bifidobacteria
strains capable of using GOS as a growth substrate, however what actually
differentiates these two groups is still unknown. In several of the studies, a
prebiotic effect was not observed at GOS dosage levels below 5.0 g (Table 3),
which indicates that a level of at least 5.0 g is needed to elicit a bifidogenic effect.
All of the studies reported a return to the initial bifidobacteria population once the
consumption of GOS was no longer continued, indicating the stability of the
gastrointestinal microbiota of adults. This return to the initial levels of microbiota
also indicates that continual consumption of GOS, or the selected prebiotic, will
be needed in order to maintain the increased levels of bifidobacteria required for
health benefits and disease prevention. The GOS, even at levels of 15 g/day,
was well tolerated by adults throughout all of the studies, with only a slight
increase in flatulence detected. These studies also showed that GOS can be
incorporated into powders, liquids, or solid foods and still exhibit the same
prebiotic effects, which is beneficial to the food industry as products are
continually being developed. The future of prebiotics, especially GOS, is
promising for the health of human adults, however further research is needed to
fully understand all of the effects and the possible relationships to diseases.
Elderly adults. As life expectancy throughout the world has rapidly risen,
heightened attention has been placed on physiologic and health needs of those
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persons over the age of 60 years. Aging is associated with changes in the
function of many organs and tissues, including the gastrointestinal tract. The
gastrointestinal microbiota evolves with age and the composition of the elderly
microflora differs from that of younger adults and infants (100). Putrefactive
bacteria, such as clostridia and enterobacteria have been reported to increase in
several studies, at the expense of more beneficial groups, most importantly
bifidobacteria (27, 40, 58, 59). The aging process is also associated with a
marked decline in immune function (immunosenescence), which can promote
hyporesponsiveness to vaccination and a predisposition to infectious and
noninfectious diseases (5). The intake of food and fluid also decreases, as does
physical activity in elderly adults. This, in combination with the use of a wide
range of medication that elderly people often use, can cause constipation. As
described earlier, reports of increased indigenous bifidobacteria in infants and
adults have been observed with the supplementation of GOS in the diet.
Studies, however, have not fully determined their effect on elderly persons.
Recent research has turned its focus to the use of prebiotics, in particular GOS,
in order to increase bifidobacteria populations in elderly with hopes of increased
immune function as well as relief of constipation.
For elderly human subjects, data is scarce and contradictory for
modulation of the gastrointestinal microflora by GOS, however results are
promising (Table 4). Studies performed by Ito et al (1993) and Vulevic et al
(2008) showed that administration of GOS, at as little as 2.5 g/day, resulted in a

Table 4. Elderly adult studies with the prebiotic galactooligosaccharide (GOS)

Type

Dose

Subjects

No

Length
of study

Objectives

Result

Reference

Ito et al. (1993)

Single-blind
randomized
controlled study

2.5 g/d of GOS

Elderly Men

n=12

3 weeks

Determine the effect of
GOS on the human fecal
microflora on elderly
persons who have low
indigenous bifidobacteria

Number of bifidobacteria
was slightly increased
after consumption of
GOS

Double-blind
placebo controlled
randomized
cross-over study

10 g/d of GOS

Elderly adults
self-reported
constipation

n=41

56 days

Evaluate the diversity and
temporal stability of
predominant fecal bacteria
populations in elderly
suffering from constipation

No effect to diversity and
Maukonen
temporal stability of selected et al. (2008)
bacterial groups was observed.
Elderly did exhibit higher
numbers of predominant
groups than younger adults

Double-blind
placebo controlled
randomized
cross-over study

5.5 g/d of GOS

Elderly adults

n=44

28 weeks

Assess the effect of a
prebiotic GOS mixture
on immune function and
fecal microflora of elderly
adults

GOS significantly increased Vulevic
bifidobacteria, phagocytosis, et al. (2008)
NK cell activity, and antiinflammatory cytokine
interleukin-10. A significant
reduction in pro-inflammatory
cytokines was also observed

Double-blind
two period
cross-over study

9 g/d of GOS

Elderly adults
Females

n=14

6 weeks

Investigate whether a
daily intake of 9 g/d of
GOS relieves constipation

Weekly defecation frequency Teuri et al. (1998)
was higher and stools were
softer during GOS consumption
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significant increase in bifidobacteria. Vulevic and colleagues (2008) also
observed that at 5.5 g/day, there was a significant decrease in less beneficial
bacterial, which suggests that GOS is an attractive option for enhancement of
both the gastrointestinal tract and immune system. Another study performed by
Maukonen and colleagues (2008), showed contradictory results as consumption
of GOS did not significantly affect the diversity or temporal stability of selected
bacterial populations. Reasons for this could be associated with the type and
purity of the GOS used, or linked to the ability of the selected subjects to respond
to the GOS, as discussed earlier. A study by Teuri and colleagues (1998)
focused on relieving constipation in elderly through consumption of GOS. They
observed a higher frequency of defecation along with softer stool sample. A
dose of 9 g/day of GOS relieved constipation by making defecation easier. Due
to the fact that laxatives often have unwanted side effects and some humans are
able to build up a gastrointestinal tolerance, an alternative for the use of laxatives
in elderly to relieve constipation has gained considerable attention. GOS has
proven to be a promising alternative as some researchers have suggested that a
reduction in the number of bifidobacteria has been related to constipation and
thus treatment with GOS increases the number of bifidobacteria can therefore
benefit bowel function (36), however further research is still needed.
Gastrointestinal diseases. Irritable bowel syndrome (IBS) is the most common
functional gastrointestinal disorder. Multidisciplinary approaches have been
proposed based on what is known of its pathophysiology, however IBS continues
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to represent a significant therapeutic challenge (50, 81). Current interest has
focused on the role of the gastrointestinal microbiota-mucosa interactions linked
to inflammatory and immune processes. With studies finding benefits pointing to
the increase in the bifidobacteria populations by the use of the prebiotic GOS,
studies are now investigating the efficacy of GOS as therapy in patients with IBS.
The use of GOS as therapy for IBS patients is very recent and not well
explored. In an animal study performed by Holma et al (2002), an increase in
bifidobacterial numbers was observed however, there was no reduction in
inflammatory processes with the consumption of GOS. A clinical trial by Silk et al
(2009) found that GOS had bifidobacterial enhancing effects in IBS patients at a
dose of 3.5 g/day and 7.0 g/day (Table 5). This increase in the levels of
bifidobacteria became similar to those of healthy humans. They also reported
that consumption of GOS was effective in alleviating symptoms associated with
IBS. These findings, although several more studies are needed, suggest that the
prebiotic GOS has the potential to act as a therapeutic agent in IBS, which is a
significant step forward.

Table 5. IBS adult studies with the prebiotic galactooligosaccharide (GOS)

Type

Randomized
parallel
cross-over study

Dose

3.5 or 7.0 g/d of GOS

Subjects

Rome II
positive IBS

No

n=44

Length
of study

12 weeks

Objectives

Result

Reference

Investigate the efficacy
of a novel prebiotic in
changing the colonic
microflora and improve
IBS symptoms

GOS treatment resulted in
Silk et al. (2009
significantly higher
proportions of bifidobacteria.
7.0 g/d resulted in significantly
lower C. perfringens and bacteroides
populations. Reported improved
stool consistency, flatulence, bloating,
and composite score symptoms
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Conclusion
Prebiotics, especially GOS, are commonly being used as functional ingredients in
infant formulas as well as a variety of food products. The consumption of GOS
has unquestionably been shown to have a wide variety of metabolic
consequences in the human gastrointestinal tract. A vast majority of the
investigations into GOS and its effects on the human gastrointestinal microflora
have shown its selectivity toward only a few bacterial groups, mainly
bifidobacteria. This selectivity has usually only been characterized to the genus
level, however researchers are beginning to take advantage of the advanced
analytical technologies that have become available for detailed community
analysis. Utilizing these advanced technologies, the global effect of prebiotic use
on microbial community structure will begin to shed light on the possibilities that
prebiotic consumption has. Characterizing these populations beyond the genus
level will also help in providing which species have distinct health-promoting
properties, as it is unlikely that all of the bifidobacteria colonizing the colon do.
Future work with well designed human investigations is still needed to establish
prebiotic needs. In particular, further studies are needed to establish the
potential role of dietary manipulation for allergy/disease prevention, immune
modulating effects of prebiotics in babies and in elderly, and to ascertain whether
these effects are long lasting. The optimal dose of GOS for specific subject
groups also needs to be determined to help in selecting the proper treatment
prior to consumption. In addition, processing procedures may alter the prebiotic
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carbohydrate profile in food, which could subsequently affect the digestion and
fermentation pathways. Therefore, an understanding of whether the prebiotic
activity is maintained after food processing treatments is needed to substantiate
the use of GOS as a functional food ingredient. GOS as a prebiotic has
undoubtedly played a role in the treatment of IBD however, it is important that
systematic studies are instigated to test for GOS benefits on all levels, as well as
within a variety of age groups. The future holds promise as a considerable
amount of prebiotic literature and research is quickly taking off.
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Abstract
The goal of this research was to determine the effect of different doses of
galactooligosaccharide (GOS) on the fecal microbiota of healthy adults, with a
focus on bifidobacteria. The study was designed as a single-blinded study, with
eighteen subjects consuming GOS-containing chocolate chews at four increasing
dosage levels; 0, 2.5, 5.0, and 10.0 g. Subjects consumed each dose for 3
weeks, with a two-week baseline period preceding the study and a two-week
washout period at the end. Fecal samples were collected weekly and analyzed
by cultural and molecular methods.

Cultural methods were used for

bifidobacteria, Bacteroides, enterobacteria, enterococci, lactobacilli, and total
anaerobes; culture-independent methods included denaturing gradient gel
electrophoresis (DGGE) and quantitative real-time PCR (qRT-PCR) using
Bifidobacterium-specific primers.

All three methods revealed an increase in

bifidobacteria populations, as the GOS dosage increased to 5 or 10 g.
Enumeration of bifidobacteria by qRT-PCR showed a high inter-subject variation
in bifidogenic effect and indicated a subset of 9 GOS responders among the
eighteen subjects. There were no differences, however, in the initial levels of
bifidobacteria between the responding individuals and the non-responding
individuals. Collectively, this study showed that a high purity GOS, administered
in a confection product at doses of 5 g or higher, was bifidogenic, while a dose of
2.5 gram showed no significant effect. However, the results also showed that
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even when GOS was administered for many weeks and at high doses, there
were still some individuals for which a bifidogenic response did not occur.
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Introduction
The large intestine of humans harbors a complex, cell rich, and diverse microbial
community consisting of hundreds of different bacterial species (Eckburg et al.,
2005; Moore et al., 1978). Included within this microbiota are organisms whose
presence is associated with, or that contribute to the health of the host (Neish,
2009).

In particular, bifidobacteria have long been suggested to play an

important prophylactic and therapeutic role in colonic health (Leahy et al., 2005).
Although these bacteria are present in large numbers in infants, and are the
dominant group in breast-fed individuals, they become less numerous after
weaning (Fooks and Gibson, 2002; Mackie et al., 1999). Due to the suggested
health benefits these bacteria provide to the host, efforts to enrich the
bifidobacteria population are now of considerable interest.
One of the primary ways by which the composition of the intestinal microbiota
can be modified is via introduction of prebiotics into the diet (Gibson and
Roberfroid, 1995; Roberfroid, 1998).

Currently, a prebiotic is defined as “a

selectively fermented ingredient that allows specific changes, both in the
composition and/or activity in the gastrointestinal microbiota that confers benefits
upon host well-being and health” (Roberfroid, 1998). Among the most widely
studied and commercially used prebiotics are inulin, fructooligosaccharides
(FOS), and galactooligosaccharides (GOS).

The latter refer to a group of

oligomeric, non-digestible carbohydrates that are produced from lactose using β-
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galactosidases to catalyze transgalactosylation reactions (Macfarlane et al.,
2008; Sako et al., 1999). These β-linked glycosides are recalcitrant to digestion
by host-secreted enzymes in the small intestine, such that they reach the colon
intact. They then become available to those members of the colonic microbiota
metabolically equipped to metabolize these specific oligosaccharides (Alander et
al., 2001; Ito et al., 1993; Tannock et al., 2004).
Numerous in vivo studies have assessed the effect of GOS on the intestinal
microbiota of infants (Chouraqui et al., 2008; Fanaro et al., 2008; Nakamura et
al., 2009), pre-term infants (Westerbeek et al., 2010), pregnant women and
neonates (Shadid et al., 2007), intestinal bowel disease patients (Silk et al.,
2009), elderly adults (Maukonen et al., 2008, Sairanen et al., 2007; Teuri and
Korpela, 1998), and healthy adults (Alander et al., 2001; Alles et al., 1999;
Bouhnik et al., 1997, 2004; Malinen et al., 2002; Satokari et al., 2001; Tannock et
al., 2004; Tiihonen et al., 2008; Vulevic et al., 2008 ). These studies used doses
ranging from as little as 2.5 g per day of GOS to as high as 15 g per day, and
relied on cultural as well as molecular methods to measure changes in the
microbiota. Although significant increases in the bifidobacteria population were
observed in several of these studies (Bouhnik et al., 1997, 2004; Depeint et al.,
2008; Vulevic et al., 2008), in other studies bifidogenic effects were not apparent
(Alles et al., 1999). Differences in the type, purity, and composition of the GOS
used in these studies, as well as difference in experimental design and methods
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of analysis, have likely contributed to these varying outcomes (Macfarlane et al.,
2008).
The goal of this study was to obtain a more detailed understanding of the effect
of GOS on the composition of the human gut microbiota and to determine the
dose necessary to achieve a prebiotic or bifidogenic effect. Both culture-based
and molecular methods were used to enumerate and characterize shift in
selected bacterial populations in eighteen blinded subjects that consumed GOS
that had been incorporated into a caramel-like, chewable confection product.
The experiment was designed such that subjects were given these GOScontaining products in sequentially higher doses (from 2.5 g to 10 g per day) so
that the dosage necessary to elicit a bifidogenic effect could be determined.

Materials and methods
Preparation of chocolate chews
Chocolate-flavored chewable candies (chews) containing GOS and control
chews (with no GOS) were prepared at the University of Nebraska-Lincoln Food
Processing Center. The GOS used was Purimune™, a high purity GOS powder
(91.8% on a dry basis) provided by GTC Nutrition (Golden, CO). The balance of
the GOS contained lactose (7%), glucose (<1%), and galactose (<0.5%). The
chocolate chews were formulated to contain 1.25 g of GOS per 6 g chew.
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Additional corn syrup and sucrose were included in the control chews containing
no GOS. The formulations of both the GOS and control chew are shown in Table
1. Chews were wrapped individually in wax paper and stored in sealed plastic
bags at 20˚C. The chews were distributed to subjects on a weekly basis.
Experimental design
The study included 21 healthy human volunteer subjects that were recruited on
the University of Nebraska-Lincoln campus. None of the subjects had been on
antibiotics or on a vegetarian diet within three months prior to the start of the
study or during the study.

Subjects were allowed to maintain their normal

lifestyles without any additional restrictions on their diets. Two subjects dropped
out of the study for reasons unrelated to the experiment and one subject was
released from the study due to pregnancy. Thus, a total of eighteen subjects, 13
males and 5 females, between the ages of 19 and 50 years old, completed the
study. The study was conducted over a 16 week period. A two-week baseline
period (no chews administered) was conducted at the beginning of the study,
followed by four sequential testing periods during which chews were
administered for three weeks with GOS dosages at levels of 0.0 g, 2.5 g, 5.0 g,
and 10.0 g GOS per day. Subjects were blinded in terms of the dose of GOS
they received, and instructed to consume eight chews per day during each
testing period, with the only difference being the number of GOS-containing
chews included in the daily regimen, which could not be differentiated from
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control chews. Thus, during the control period, 8 control chews were consumed,
and during the 2.5 g treatment period, 2 GOS chews (each containing 1.25 g
GOS) and 6 control chews were consumed. The 5 g treatment period included 4
GOS and 4 control chews and the 10 g treatment consisted of 8 GOS chews. A
final two-week washout period (no chews) was performed at the end of the fourth
testing period.

All of the dosages were sequential with no washout periods

between dosages. Subjects were asked to report the presence, absence, and
severity of gastrointestinal symptoms experienced throughout each week of the
study. The symptoms survey was based on previously reported studies (Bouhnik
et al., 1997, 2004; Shadid et al., 2007) and included bowel movement, stool
consistency, discomfort, flatulence, abdominal pain, and bloating, and were
scored on a one (none, normal, good well-being) to five (severe symptoms and
discomfort) scale provided as part of weekly subject diaries. The study was
approved by the Institutional Review Board of the University of Nebraska.
Collection and processing of fecal samples
Fecal samples were collected weekly from each subject.

Each sample was

processed within 1 hour of a bowel movement. All fecal samples (1.0 g) were
weighed and diluted 10-fold with sterile phosphate buffered saline (PBS; pH 7.0).
Samples were homogenized and immediately frozen at -80°C and saved for DNA
extraction.

Fecal samples (1.0 g) were also immediately introduced into an

anaerobic chamber (Bactron IV Anaerobic Chamber, Shel Lab, Cornelius, OR)
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and a 10-fold dilution series was made with pre-reduced sterile saline (0.9%
NaCl). Aliquots were plated on Brain Heart Infusion Agar (Becton Dickinson; BD,
Franklin Lakes, NJ) for total anaerobes (incubated 48 h), Rogosa SL (BD) for
Bifidobacterium (96 h), and Bacteroides Bile Esculine Agar (BD) for Bacteroides
(48 h). All plates were incubated anaerobically at 37°C. In addition, the Rogosa
SL agar plates that were used to enumerate bifidobacteria were also examined at
48 h to estimate lactobacilli levels.

Serial dilutions were also used to plate

aliquots aerobically on MacConkey Agar (BD) for enterobacteria (24 h), and Bile
Esculin Azide Agar (Acumedia, USA) for enterococci (48 h).
incubated aerobically at 37°C.

Plates were

These organisms were chosen for cultural

enumeration based on previous prebiotic and probiotic feeding studies (Tannock
et al., 2000, 2004).
The fecal pH was measured in aqueous slurries using an Ag/AgCl pH meter
(Accumet Basic AB15pH meter, Fisher Scientific).

Statistical analysis was

completed using a one-way ANOVA as well as Tukey’s post-hoc pair-wise
comparison test.
DNA extraction
A 1 mL aliquot of a 1:10 diluted fecal sample in PBS was transferred to sterile
bead beating tubes (Biospec products, Bartlesville, OK, USA) containing 300 mg
of zirconium beads (0.1 mm). Fecal cells were washed three times in chilled
PBS using centrifugation at 6,000 x g for 5 min. Pellets were resuspended in 100
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µL of lysis buffer (200 mM NaCl, 100 mM Tris, 20 mM EDTA, 20 mg/mL
Lysozyme, pH 8.0) and incubated at 37°C for 30 min. Buffer ASL (1.6 mL) from
the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) was added to each
sample after the samples were homogenized in a MiniBeadbeater-8 (BioSpec
Products, OK, USA) for two min at maximum speed. The DNA was purified from
the supernatants using the QIAamp DNA Stool Mini Kit, following the Qiagen kit
manufacturer’s instructions.
Quantitative real time-PCR
Quantitative real time PCR (qRT-PCR) was performed as described by Martínez
et al. (2009) using a Mastercycler Realplex2 (Eppendorf AG, Hamburg,
Germany)

with

Bifidobacterium-specific

primers

F:

5’TCGCGTC(C/T)GGTGTGAAAG’3 and R: 5’CCACATCCAGC(A/G)TCCAC’3
(Martínez et al. 2009, Rinttila et al. 2004), with an amplicon size of 243 bp.
Standard curves for absolute quantification of bifidobacteria in the fecal samples
were prepared using overnight cultures (14 h) of Bifidobacterium animalis ATCC
25527T and Bifidobacterium infantis ATCC 15697T.

For each qRT-PCR

experiment, a standard curve was prepared, in duplicate, using DNA extracted
from cultures at concentrations ranging from 105-108 CFU/mL.
coefficients for all standard curves were above 0.95.
Analysis by PCR-DGGE

Correlation
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PCR-DGGE was performed as described by Martínez et al. (2009). Briefly, the
V3 region of the 16S rRNA gene was amplified by PCR using universal primers
PRBA338fGC
(5’CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGACTCCT
ACGGGAGGCAGCAG’3)
(Ovreas et al., 1997).

and

PRUN518r

(5’ATTACCGCGGCTGCTGG’3)

Denaturing Gradient Gel Electophoresis (DGGE) was

performed as described previously (Walter et al., 2000), using a DCode universal
mutation detection system (Bio-Rad, Hercules, USA). Band fragments of interest
were excised, repeatedly purified (Walter et al. 2001), and then cloned using the
TOPO® TA Cloning® Kit for Sequencing (pCR® 4 TOPO® Vector) (Invitrogen).
The QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) was used to isolate
plasmids from transformants, and inserts were sequenced by a commercial
provider. Closest relatives of the partial 16S rRNA sequences were determined
using the SeqMatch web tool provided through the Ribosomal Database Project
(http://rdp.cme.msu.edu).
BioNumerics software Version 5.0 (Applied Maths) was used to analyze DGGE
profiles. DGGE bands were automatically assigned and densitometric curves
were obtained based on the staining intensity profiles generated by the
BioNumerics software. Band staining intensities were calculated as a percent of
each peak area of the entire fingerprint generated for the individual sample. We
have previously determined the reliability of this quantification method by
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comparing taxa abundance inferred by DGGE band intensities with those
obtained with pyrosequencing of 16S rRNA tags in studies on the hamster
microbiota, and received correlations of r > 0.8 (Martínez et al., 2009).
Statistical analysis
One-way ANOVA tests with repeated measures were used to determine
significance between the different doses of GOS (0, 2.5 g, 5 g, and 10 g) and the
control. Baseline/washout samples were combined for the analysis and referred
to as “none”’. Statistical analysis was performed for the combined data from the
eighteen subjects and to identify statistically significant increases of individual
subjects. Tukey’s test was used for post hoc pair-wise comparisons.

Results
Digestive tolerance of GOS
All eighteen subjects completed a weekly symptoms diary throughout the
duration of the study. These symptoms diaries allowed subjects to rate bowel
movement, stool consistency, discomfort, flatulence, abdominal pain, and
bloating on a scale of one (none, normal, good well-being) to five (severe
symptoms and discomfort).

Based on a one-way ANOVA of the data, no

significant differences were detected for any of the symptoms between the 0.0 g
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GOS control dose and any of the GOS treatments (Table 2).

A significant

symptom change was observed for flatulence (p < 0.05), but only between the
baseline and washout and the treatment periods. However, the increase in this
score occurred not only for the GOS treatments, but even during consumption of
the 0.0 g GOS control period.
Fecal bacteria counts
Cultural enumerations were performed for total anaerobic bacteria and for
lactose-fermenting

enterobacteria,

enterococci,

Bifidobacterium,

and

Bacteroides. Lactobacilli counts were very low (< 106/g) throughout the entire
duration of the study, even during treatment periods (data not shown). When the
data for each individual subject was analyzed, the results revealed that for some
subjects, statistically significant differences in several of these groups were
observed following consumption of GOS (data not shown). When the results of
all eighteen subjects were pooled together, no significant changes were detected
for levels of Bacteroides, enterococci, or lactose fermenting enterobacteria.
However, ANOVA revealed that GOS induced a modest, but statistically
significant increase of bifidobacteria compared to the control treatment (Table 3).
This bifidogenic effect occurred when subjects had consumed the 5 g dose of
GOS, and a further increase in dose to 10 g of GOS was not significant when
compared to the 5 g dose. In contrast, however, the 10 g dose did result in a
significant increase in total anaerobes compared to the 2.5 g dose. In addition,
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we observed that the bacterial populations for all groups were similar during the
baseline and washout periods.
The pHs of all of the fecal samples (288) were determined. All but two of the
samples had pH values between 6.0 and 8.0, and there were no significant
treatment differences in pH observed over the period of the study (data not
shown).
Genus specific qRT-PCR for enumeration of bifidobacteria
The culture analysis indicated that a bifidogenic effect occurred due to
consumption of GOS, and that this effect was detectable at doses of 5 g and 10
g, with no significant differences between the two high doses. In order to confirm
these findings without a potential cultivation bias, cell numbers of bifidobacteria in
fecal samples were quantified by genus-specific qRT-PCR. As shown in Figure
1a, the Bifidobacterium population in the eighteen subjects increased with the
inclusion of chews containing different amounts of GOS. As before for cultural
enumeration, this increase reached statistical significance when 5 g and 10 g of
GOS were consumed (p < 0.001). The analysis also showed major differences in
the dose response relationships in individual subjects. In total, Bifidobacterium
numbers were significantly increased by GOS consumption in nine of the
eighteen subjects as analyzed by ANOVA. Figure 1b shows the numbers of
bifidobacteria in these nine “responders”. This data showed an equivalent
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gradual increase of bifidobacteria with dose, with no significant differences
between 5 and 10 g of GOS.
To determine if the baseline Bifidobacterium population influenced the prebiotic
effect, we compared the initial bifidobacteria levels between responders and nonresponders.

The Student’s t test did not reveal any significant differences

between these groups (data not shown), indicating that initial number of
bifidobacteria did not determine whether any specific individual was a responder
or non-responder. In contrast, the baseline cell count of bifidobacteria in subjects
was a major determinant for the bifidogenic effect when this effect was based on
the difference in actual numbers from the baseline to the average of the 5 and 10
g treatments.

As shown in Figure 2A, initial levels of bifidobacteria directly

correlated with the increase of bifidobacteria numbers. However, the bifidogenic
effect, expressed as the “log increase”, was inversely correlated with the initial
bifidobacteria levels (Figure 2B). In other words, subjects with low numbers of
bifidobacteria had a higher potential for the prebiotic to induce a 100-1000 fold
increase, while subjects that already possessed high levels of bifidobacteria were
able to achieve an even higher increase in absolute numbers.
Characterization of total fecal bacterial populations by PCR-DGGE
To obtain a broader assessment of the impact of GOS on the fecal microbiota,
we used a universal PCR-DGGE approach to determine the dynamics of the
community fingerprints. These analyses revealed a high level of stability among
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the gut microbiota in all of the subjects. The DGGE gels corresponding to the
eight subjects with the most pronounced changes in staining intensities upon
consumption of GOS are shown in Figure 3.

Quantification of DGGE band

intensities was then performed using BioNumerics software, as previously
reported (Martínez et al., 2009), revealing several major effects (Table 4).
The most consistent alteration in band staining intensity resulting from
consumption of GOS was a band at the bottom of the DGGE gels (labeled as C,
G, H, I, and L), that was present in five subjects, 2, 4, 14, 15, and 17 (Figures 3A
and 3B). Excision of the band and subsequent purification and DNA sequencing
revealed that the band corresponded to Bifidobacterium adolescentis (Table 5).
The staining intensity of this band clearly showed a dose dependent increase
(Table 4), although differences were observed between subjects with respect to
the effective dose (ranging from 2.5 – 10 g). However, when the band intensity
values from these five subjects were averaged, the results revealed that a
bifidogenic effect occurred only when the GOS dose reached 10 g (Figure 3C).
Collectively, the abundance of B.adolescentis, as determined by staining
intensity, was remarkably quantitative and highly correlated to cell numbers as
determined by qRT-PCR (Figure 3D). Also, as shown in Figure 3 and Table 4,
the increase in B. adolescentis was reversible and returned to the baseline level
within a week of wash out. Consumption of GOS also resulted in several other
reversible alterations in the fecal microbiota; however, most of these alterations
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related to a decrease in staining intensity of bands that corresponded to different
colonic microorganisms (Table 5).

Discussion
The ability of GOS to effect changes in the microbiota of the human intestinal
tract was first reported in 1993 (Ito et al., 1993).

Although increases in the

bifidobacteria population in test subjects were reported in this and many other
studies (Bouhnik et al., 1997, 2004; Depeint et al., 2008; Vulevic et al., 2008), in
other investigations a bifidogenic effect of GOS was not detected (Alles et al.,
1999; Malinen et al., 2002). Variations in the GOS type, dosage, the delivery
vehicle, and in the experimental design likely account for some of these different
outcomes. However, the methods of analysis may have also contributed to these
differences, especially when enumeration was based primarily on cultural
methods.
In this study, three independent techniques (group-specific culturing, qRT-PCR,
and PCR-DGGE) were used to study the impact of different doses of a highly
pure source of GOS on the human gut microbiota in eighteen healthy subjects.
The GOS was incorporated into chewable confections, delivered in sequentially
higher doses, and all of the subjects were blinded. Samples were obtained and
analyzed three times during each of the four treatment periods, and twice during
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both the baseline and washout periods. In general, the cultural enumeration
results during the baseline period were consistent with other reports utilizing
similar techniques to quantify members of the gastrointestinal microbiota
(Tannock et al., 2000, 2004). The low levels of lactobacilli in most of the subjects
throughout the study were also consistent with previous observations (Eckburg et
al., 2005; Tannock et al., 2000; Walter, 2008). Importantly, however, all three
methods clearly confirmed a highly significant bifidogenic effect of GOS that was
quickly reversed when GOS consumption had ended. In addition, the results
indicated that the effect was dose-dependent. Although we detected a modest
increase of bifidobacteria numbers by cultural and qRT-PCR methods at a daily
dose of 2.5 g of GOS, it required 5 g per day to achieve statistically significant
higher numbers of bifidobacteria, relative to the control. A further increase in the
dose from 5 to 10 g of GOS did not lead to an additional increase in the absolute
number of bifidobacteria when determined by both culture and qRT-PCR (Table
3, Figure 1).
Collectively, the data obtained in this study suggests that the dose does influence
the bifidogenic effect of a prebiotic food product. However, it has previously
been suggested that the daily dose of a prebiotic is not a determinant of the
prebiotic effect (Gibson et al., 2004; Roberfroid, 2007).

According to this

argument, the prebiotic effect is influenced by the starting number of
bifidobacteria in the subjects prior to administration of the prebiotic, such that the
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larger the number of initial fecal bifidobacteria present in an individual, the
greater is the potential for a bifidogenic effect. Thus, increases in bifidobacteria,
in absolute numbers, in response to prebiotics directly correlate with the initial
number, but inversely correlate with log transformed increases.

Our results

support this conclusion, as we observed that the greatest bifidogenic response to
GOS, in absolute numbers, occurred in subjects having the highest initial
bifidobacteria levels, while a higher log increase was observed in subjects with
low initial numbers (Figure 2). However, our data still clearly indicates that the
dose of GOS was an important determinant of the prebiotic effect. As shown
above, when all eighteen subjects were considered, a significant bifidogenic
effect required 5 g of GOS, relative to the control, whereas 2.5 g was not
sufficient. The data suggests that a minimum or ‘threshold’ dose may exist below
which a prebiotic effect is not observed. Accordingly, in a previous study, 2.5 g of
GOS did not lead to an increase in cell numbers of bifidobacteria (Tannock et al.,
2004). However, our data does also indicate that there may also be a dose at
which no additional bifidogenic effect is observed (i.e., above 5 g in our study).
Above this threshold, the dose of a prebiotic is indeed not a determinant of the
prebiotic effect, as suggested by Gibson and Roberfroid (Gibson et al., 2004;
Roberfroid, 2007). We suggest, however, that the determination of a prebiotic
dose or threshold, as determined in this study, is valuable for dietary
recommendations, as this amount constitutes a minimum dose by which a
significant bifidogenic effect can be achieved in a population of subjects.
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Although all three methods of analysis showed that GOS could elicit a bifidogenic
response when the results from the 18 subjects were pooled, we also observed
considerable individual variations. Thus, only 50% of the subjects showed a
statistically significant increase of bifidobacteria following GOS consumption.
What differentiates these responders from non-responders is unknown, but we
suggest that one explanation may simply be due to the presence or absence of
specific Bifidobacterium strains capable of using that prebiotic as a growth
substrate. Thus, responders may harbor a greater proportion of GOS-fermenting
bifidobacteria
individuals.

among

the

gut

microbiota,

compared

to

non-responding

Although we did not detect differences in the initial numbers of

bifidobacteria in responders and non-responders, individuals in the latter group
might nonetheless lack specific GOS-utilizing strains. In addition, although the
effective bifidogenic dose was 5 g for the subjects on average, subject-specific
dose-response relationships were also detected (data not shown).
In this study, we incorporated the GOS into a chewable confection product to
simulate a relevant means of delivery. Preliminary evaluations indicated that the
control and GOS-containing chews were indistinguishable based on appearance,
flavor, and chewiness. All of the GOS dosage levels used in this study, including
the 10 g per day dose, were well tolerated, based on the absence of any adverse
effects compared to the control chews as reported in the symptoms diaries.
Although subjects did report an increase in the flatulence score, significance
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occurred between the baseline period and even the control (no GOS) treatment,
suggesting that this outcome was due either to a placebo effect or was caused
by another component of the chew. Moreover, no differences in flatulence were
reported between any of the treatment doses. The general tolerance of GOS
and the absence of undesirable side-effects at these dosages has previously
been reported (Ito et al., 1990).
Several reports have shown that DGGE is an effective method to assess the
effect of GOS consumption on the stability and diversity of the human intestinal
microbiota (Maukonen et al., 2008; Tannock et al., 2004). In the latter study, the
DNA-DGGE profiles were not altered in healthy adults following consumption of
GOS-containing biscuits (2.5 g per day for three weeks), although changes in the
RNA-derived DGGE profiles were observed. The RNA-DGGE fragments whose
intensity had increased during GOS were sequenced and subsequently assigned
to Bifidobacterium adolescentis and/or Colinsella aerofaciens. In the current
study, DGGE analysis provided evidence that consumption of GOS induced
compositional alterations in the fecal microbiota of a majority of subjects.
Moreover, the DGGE results showed that the changes in the microbiota were
selective, with the most consistent alteration detected being an increase in the
intensity of a band corresponding to Bifidobacterium adolescentis.
Although specific health benefits have not yet been causally linked to particular
bacterial populations in the human gut, bifidobacteria are generally considered to
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be health-promoting organisms and constitute one of the main groups of
organisms targeted by prebiotics.

In this study, we provide evidence that a

minimum dose of 5 g of GOS per day induced significant alterations in the gut
microbiota in healthy human adults, mainly by increasing the number of
bifidobacteria. We argue that dose-response studies such as the one presented
here might enable better dietary recommendations on an effective dosage of
prebiotics, especially when incorporated directly into foods. However, as shown
in this study, it appears that even when GOS is administered for many weeks
and at high doses, there may still be some individuals for which a bifidogenic
response does not occur.
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Table 1. Composition (%) of chocolate chews
Ingredient

Control Chocolate Chew

GOS Chocolate Chew

Water

11.62

11.54

Sugar

27.35

19.42

GOS (Purimune)

0.00

23.40

Corn Syrup

44.84

31.83

Palm Kernel Oil

7.62

5.41

Chocolate Liquor (1/2 Bakers)

7.58

7.44

Lecithin

0.55

0.53

Vanilla

0.44

0.43
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Table 2. Mean ± standard deviations of weekly symptoms. Reported on a scale of 1 (best) to 5 (worst).
Baseline

0.0 g

2.5 g

5.0 g

10.0 g

Washout

Bowel Movement

1.42 ± 0.55

1.57 ± 0.61

1.44 ± 0.55

1.39 ± 0.51

1.46 ±0.61

1.42 ± 0.79

Stool consistency

1.56 ± 0.64

1.63 ± 0.68

1.54 ± 0.68

1.54 ± 0.73

1.57 ± 0.65

1.50 ± 0.84

Discomfort

1.42 ± 0.69

1.48 ± 0.60

1.56 ± 0.57

1.44 ± 0.65

1.52 ± 0.73

1.14 ± 0.38

Flatulence

1.52 ± 0.78

1.83 ± 0.75

*

1.85 ± 0.79

1.86 ± 0.75*

2.07 ± 0.88*

1.25 ± 0.55

Abdominal pain

1.17 ± 0.38

1.31 ± 0.49

1.33 ± 0.40

1.30 ± 0.50

1.30 ± 0.60

1.14 ± 0.41

Bloating

1.14 ± 0.33

1.39 ± 0.75

1.43 ± 0.47

1.30 ±0.65

1.48 ± 0.90

1.08 ± 0.26

*

*Significant differences detected by ANOVA (p < 0.05) between the GOS and baseline and washout treatments.
Tukey’s post-hoc test did not detect significant differences in pair wise comparisons.
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Table 3. Enumeration of bacterial groups through culturing
Log 10 cfu/g feces (Mean ± SD)
Bacterial group

Baseline

0.0 g

5.0 g

10.0 g

Washout

5.60 ± 1.14

5.68 ± 1.07

5.64 ± 0.86

5.18 ± 1.26

5.59 ± 0.85

5.78 ± 1.17

Enterococci

5.02 ± 0.99

5.02 ± 1.07

4.95 ± 0.99

4.67 ± 0.93

4.70 ± 0.90

5.13 ± 1.10

Bifidobacteria

9.32 ± 0.79

9.48 ± 0.73

9.60 ± 0.80

9.76 ± 0.48*

9.83 ± 0.56***

9.42 ± 0.52

Bacteroides

9.56 ± 0.37

9.58 ± 0.37

9.59 ± 0.35

9.47 ± 0.32

9.53 ± 0.35

9.53 ± 0.33

Total anaerobes

10.19 ± 0.28

10.19 ± 0.20

10.11 ± 0.23

10.24 ± 0.15

Lactose fermenting

2.5 g

Enterobacteria

10.35 ± 0.16**§§§

10.19 ± 0.21

Significantly different to 0.0 g: * (p < 0.05), ** (p < 0.01), *** (p < 0.001)
Significantly different to 2.5 g: §§§ (p < 0.001)
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Table 4. Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%) and results of sequence analysis of selected
bands.

Baseline

0.0 g

Mean band intensity (± SD)
Increasing significance
2.5 g
5.0 g

Subject DGGE
fragment
2
C

10.0 g

Washout

3.68 ± 0.02

2.76 ± 0.009

4.87 ± 0.01

6.67 ± 0.03

11.89 ± 0.04**§

2.93 ± 0.02

4

F

3.13 ± 0.02

1.23 ± 0.001

3.83 ± 0.02

3.33 ± 0.005

6.96 ± 0.02**

1.39 ± 0.002

G

1.46 ± 0.007

3.94 ± 0.02

2.70 ± 0.004

5.51 ± 0.01

9.75 ± 0.03*§§

1.21 ± 0.003

14

H

3.41 ± 0.16

6.40 ± 0.06

8.57 ± 0.02

7.41 ± 0.008

8.06 ± 0.02

0.69 ± 0.01

15

I

0.00 ± 0.00

0.00 ± 0.00

1.48 ± 0.002*

2.53 ± 0.01**

2.55 ± 0.002**

0.00 ± 0.00

17

L

0.92±0.002

1.73±0.01

1.48±0.01

5.15±0.007

10.00±0.03***§§§†

0.60±0.002

Decreasing significance
1

A

11.91 ± 0.03

10.73 ± 0.03

2.79 ± 0.05*

0.12 ± 0.001**

0.19 ± 0.002**

1.15 ± 0.01

2

B

5.07 ± 0.01

3.50 ± 0.01

3.17 ± 0.01

2.88 ± 0.003

1.03 ± 0.002

2.51 ± 0.01

3

D

6.51 ± 0.02

7.06 ± 0.03

3.42 ± 0.04

1.30 ± 0.02

0.001 ± 0.002

4.50 ± 0.004

4

E

1.88 ± 0.001

1.66 ± 0.005

3.35 ± 0.003

2.69 ± 0.02

0.35 ± 0.0009§

2.63 ± 0.02

16

J

9.74 ± 0.03

8.00 ± 0.03

7.15 ± 0.009

4.13 ± 06

4.10 ± 0.005

4.33 ± 0.004

17

K

8.70 ± 0.002

3.68 ± 0.04

6.79 ± 0.02

2.80 ± 0.02

0.63 ± 0.005

2.83 ± 0.004

Significantly different to 0.0 g: * (p < 0.05), ** (p < 0.01), *** (p < 0.001)
Significantly different to 2.5 g: § (p < 0.05), §§ (p < 0.01), §§§ (p < 0.001)
Significantly different to 5.0 g: † (p < 0.05)
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Subjects 3, 14, 2B, 16, and 17K are included because they are
approaching significance (p < 0.05) at 10 g compared to 0.0 g.

Table 5. Identification of band fragments in DGGE gels
Subject Band fragment Closest related Genbank sequence (% similarity between DGGE fragment and Genbank sequence)

1

A

Ruminococcus uncultured bacterium; 29A-b4; DQ905715 (99%)

2

B

Lachnospiraceae uncultured bacterium; RL197_aah88b02; DQ794455 (100%)

C

Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%)

3

D

Bacteroides uncultured bacterium; NO48; AY916250 (100%)

4

E

Bacteroides uniformis (T); JCM 5828T; AB050110 (100%)

F

Bacteroides dorei (T); JCM 13471; 175; AB242142 (100%)

G

Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (99%)

14

H

Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%)

15

I

Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%)

16

J

Ruminococcaceae uncultured bacterium; RL185_aan85a07; DQ825073 (100%)

17

K

Ruminococcus uncultured bacterium; B086; DQ325583 (97%)

L

Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%)
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Figure 1. Bifidogenic effect of GOS as determined by qRT-PCR for all eighteen
subjects (A) and for the 9 responders (B). Significance (by ANOVA) is indicated
at either p<0.05 (*) or p<0.001 (***).
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Figure 2. Correlation of initial bifidobacteria levels (baseline) and the increase of
bifidobacteria by GOS feeding (from the baseline to the average of the 5 and 10
g dose levels) as measured by absolute numbers (A) and by log increase (B).

87

A
12

Log 10 initial cell numbers

11

10

9
R² = 0.3948
8

7

6
10

0.0

11

5.0X10

11

1.0X10

1.50X10

Absolute increase in cell numbers

B

Log 10 initial cell numbers

12
11
10
R² = 0.5095
9
8
7
6
-1

0

1

Log10 increase in cell count

2

3

4

88
Figure 3. DGGE analysis of fecal microbiota of subjects 1, 2, 3, and 4 (A) and
14, 15, 16, and 17 (B) by DGGE. Bands that were significantly affected by the
GOS treatments are outlined. Abundance scores, as measured by DGGE band
intensities from bands, C, G, H, I, and L, as a function of GOS doses (C).
Correlation of Bifidobacterium adolescentis band intensities from subjects 2, 4,
14, 15, and 17 for all time points to cell numbers, as measured by
Bifidobacterium genus-specific qRT-PCR (D).
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ABSTRACT
The goal of this research was to gain a community wide perspective of the
impact of GOS on the fecal microbiota of healthy human subjects using high
throughput multiplex community sequencing of 16S rRNA tags. Eighteen healthy
human subjects consumed GOS containing caramel-like confectionary products
for twelve weeks, with four increasing dosages of GOS. Multiplex sequencing of
the 16s rRNA tags revealed that GOS induced significant compositional
alteration in the fecal microbial populations by increasing the phyla
Actinobacteria. At the species level, the changes evoked by GOS resulted in
increases of six of the Bifidobacterium species, including B. adolescentis, B.
longum, and B. catenulatum. The population shifts caused by consumption of
10 g of GOS were numerically substantial, leading for example, to a ten-fold
increase in bifidobacteria in four subjects, enriching them to 18-33% off the fecal
microbial community, and a five-fold increase in seven additional subjects.
Moreover, this increase in bifidobacteria abundance, to greater than 20% in
some individuals, was generally at the expense of only one group of bacteria,
namely the genus Bacteroides. The responses to GOS and their magnitudes
varied between individuals, and they were reversible and tightly associated with
the increasing dosage of GOS. Our results demonstrate that GOS is remarkable
for its ability to enrich specifically for bifidobacteria in human fecal samples,
although it is utilized by a wide variety of bacterial inhabitants of the intestinal
tract when studied in vitro.
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INTRODUCTION
It has become increasingly recognized that the gastrointestinal microbiota
plays a critical role in human health (13). The composition and activity of this
microbiota affect nutrient utilization and adsorption, the development and
maturation of the immune system, and resistance to infections (24, 43, 47).
Aberrations in the gut microbiota have been linked several complex diseases,
including inflammatory bowel disease (13, 19, 34), colitis (27, 33), osteoporosis
(1,35), obesity, atherosclerosis and cardiovascular disease (32, 44, 14), type 2
diabetes (9), colorectal cancer (21, 55,20), arthritis, and allergic diseases (26, 30,
31, 42, 59). Moreover, the discovery that it is possible to effect changes in the
intestinal microbiota by relatively small dietary modifications (35) has led to the
suggestion that these aberrations or imbalances can be corrected and host
health improved (22).
One strategy by which to modulate composition and metabolism of the
intestinal microbiota are prebiotics. Prebiotics are defined as “a selectively
fermented ingredient that allows specific changes, both in the composition and/or
activity in the gastrointestinal microbiota that confers benefits upon host wellbeing and health” (45). Several of these carbohydrates are used commercially in
foods, including inulin, fructooligosaccharides (FOS), resistant starch, and
galactooligosaccharides (GOS). There is now convincing in vivo evidence
showing that prebiotics can promote growth of bifidobacteria in the intestinal tract
of infants and adults (56). For GOS in particular, 2 to 3 log increases in the

94
number of bifidobacteria have been reported (15). However, the human gut
microbiota is composed of hundreds of species (22), and the impact of prebiotics
on other members of the intestinal microbiota and the community structure in
general is less well understood.
. The specificity of prebiotic substrates was initially attributed to their
selective fermentation in the intestinal tract. Several surveys have revealed that
several species of Bifidobacterium, as well as Lactobacillus, are able to ferment
prebiotic substrates.

Interestingly, however, in monoculture, several colonic

bacteria other than bifidobacteria have been reported to utilize prebiotics as an
energy or carbon source, including species of Clostridium, Enterococcus,
Bacteroides, and Escherichia. These groups of bacteria have previously not
been reported to be enriched through prebiotics in human trials, and other
mechanisms have been proposed for the relatively specific bifidogenic effect of
prebiotics, such as tolerance to SCFA and acidification and the ability to adhere
to prebiotic substrates (12). However, most studies on the in vivo specificity of
prebiotics applied methodologies with limitations in their ability to address the
question on how specific prebiotics are. These studies relied on either cultural
enumeration methods that fail to detect the majority of microbial species present
in the human gut (2, 8, 16, 29), or they used molecular methods that are
restricted by focusing on selected bacterial groups (qRT-PCR, fluorescent in situ
hybridization (FISH;16) or suffer from a small dynamic range (DGGE; 52,15, TRFLP). Several of these studies showed that the prebiotic response was not
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completely restricted to bifidobacteria. For example, Tannock and co-workers
showed that FOS increased staining intensities of bands corresponding to
Bifidobacterium adolescentis and Colinsella aerofaciens (52). In a study in mice,
Apajalahti and colleagues found that Inulin induced community shifts that
included increases of bifidobacteria and a decrease in clostridia, but the major
changes were observed within previously unknown taxa (3). Therefore, although
the bifidogenic effect of most prebiotic carbohydrates is clearly established, the
exact effect of prebiotics on the entire community composition and structure
remains an important field of study. Massively parallel sequencing of amplified
16s DNA tags via pyrosequencing now provides the means to quantify the fecal
microbiota at increased depth spanning the entire microbial community at very
high sensitivities. Thus, a much more detailed analysis of how prebiotics affect
the microbiota can be achieved, and community wide shifts in throughout the
entire phylogenetic spectrum of the bacterial population can be measured.
We recently reported that GOS, incorporated into caramel-like
confections, increased the amount of bifidobacteria in 9 out of 18 healthy adults
at doses above 5 g per day as assessed by specific culture, qRT-PCR, and
DGGE (15). Only one other bacterial group, Bacteroides dorei, was detected by
DGGE to become increased in one single subject, suggesting that GOS was
highly specific in its stimulation of bifidobacteria. However, techniques used in
our previous study were restricted in both depth and breadth, and the goal of this
current study was to gain an in depth perspective of the impact of GOS in these
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subjects using high throughput multiplex community sequencing of 16S rRNA
tags. We discovered that GOS was remarkable for its ability to enrich specifically
for bifidobacteria in human fecal samples, although it is utilized by a wide variety
of bacterial inhabitants of the intestinal tract in vitro. .

MATERIALS AND METHODS
Experimental design. The details for how this study was conducted were
previously described in detail (15). Briefly, caramel chews were administered to
18 healthy human volunteer during a 16 week period. The first two weeks were
established as the baseline period (no chews administered), and this was
followed by four sequential testing periods during which chews were
administered for three weeks with GOS dosages at levels of 0.0 g, 2.5 g, 5.0 g,
and 10.0 g GOS per day. A final two-week washout period (no chews) was
performed at the end of the fourth testing period (weeks 15 – 16). The study was
approved by the Institutional Review Board of the University of Nebraska.
Molecular characterization of the fecal microbial communities by
pyrosequencing of 16S rRNA tags. Fecal samples were collected weekly and
processed as described previously (15). Pyrosequencing of 16S rRNA tags was
preformed from fecal DNA as described by Martínez et. al (2010). Briefly, the V1V3 region of the 16S rRNA gene was amplified by PCR from fecal DNA using
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primers were modified to work with the Roche-454 Titanium kit. A mixture (4:1)
of the primers B-8FM
(5’CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGAGTTTGATCMTGGCTCAG3’)
and B-8FMBifido
(5’CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGGGTTCGATTCTGGCTCAG3’),
were used as the forward primers. The primer A518R
(5’CCATCTCATCCCTGCGTGTCTCCGACTCAGBBBBBBBBATTACCGCGGCTG
CTGG-3’) containing an 8-base barcode sequence was used as the reverse
primer.

Sequences were then assigned to their respective samples via the

barcode. The 8FMBifido was used in combination with primer 8FM as 16s DNA
sequences within the genus Bifidobacterium are not well amplified by the latter
primer (37).
Equal amounts of the PCR products were combined, gel purified, and
sequencing was performed by the Core for Applied Genomics and Ecology
(CAGE, University of Nebraska-Lincoln)

with the 454/Roche A sequencing

98
primer kit using a Roche Genome Sequencer GS-FLX. Using the Ribosomal
Database Project (RDP) Pyrosequencing Pipeline (http://pyro.cme.msu.edu/)
‘Initial Process’ tool, sequences were binned according to the barcode (11).
Default parameters were used to remove sequences containing any ambiguous
nucleotides, except for the minimum sequences length, which was set to 300 bp.
BioEdit Software was used to trim the quality approved sequences to 450 bp
before their submission to the sequence analyses (see below).
Sequence analyses to characterize microbial populations. Sequences
obtained

with

pyrosequencing

were

analyzed

using

two

independent

approaches, a taxonomy dependent and a taxonomy independent. First, the
Classifier tool of the RDP was applied (with a minimum bootstrap value of 80%)
to obtain a taxonomic assignment of all sequences. The Classifier approach
allowed a fast determination of the proportions of bacterial groups at different
taxonomic levels (phylum, family, and genus).

Second, sequences were

assigned to Operational Taxonomic Units (OTUs). For this, all sequences from
each subject were individually aligned using the RDP Aligner web tool, and then
clustered using the RDP Complete Linkage Clustering web tool (with a maximum
distance cutoff of 97%; 11). The OTU picking was done on a per subject base as
the entire data from all subjects contained too many sequences for a quality
alignment. Excluded from the analyses were OTUs that contained less than
three sequences. Using Statistical Analysis Software (SAS) to perform ANOVA,
the OTUs that were significantly affected by the dietary treatments in each
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subject were identified.

Representative sequences from each OTU whose

abundance was significantly influenced by GOS were subjected to taxonomic
classification using SeqMatch, an RDP web tool.

From each statistically

significant OTU identified, five random representative sequences were aligned to
form consensus sequences using SeqMan Software.

The consensus

sequences were grouped and aligned according to phylum (Actinobacteria,
Bacteroidetes, Firmicutes, Fusobacteria, Proteobacteria, and Verrucomicrobia)
together with the most closely related type strains or entry in the NCBI database
using Muscle 3.6 (18).

Phylogenetic trees were built by neighbor-joining with

1,000 bootstrap replicates with MEGA 4.0 Software (53). Using visual analyses
and a distance matrix, OTUs were assigned as sequence clusters with >97%
identity.

Quantification of the OUT in each subject was performed by BLASTn

analysis. For this, consensus sequences were generated for each of the OTU
sequence clusters as described previously. A local nucleotide database was
established through a PERL script, which combined all eighteen subjects’
sequences, detected by pyrosequencing, into one database.

A BLASTn

algorithm was used with a 97% cutoff (min. length 300 bp) to quantify each OTU
in the fecal bacterial populations within each sample. Samples that were closely
related to Bifidobacterium adolescentis were re-analyzed with a BLASTn
algorithm at a cutoff of 98% (min. length 300 bp) as clearly differentiated clusters
could be identified that showed overlap with 97% algorism. The quantification of
OTUs in all subjects was verified to ensure that individual sequences were not
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being assigned to different OTUs. In three occasions, seven OTUs that were
initially identified as distinct had very high shared sequence similarities, and were
thus merged together into three OTUs.
Determination of community diversity. Two different methods, the
generation of rarefaction curves and Shannon’s index, were applied to determine
the diversity of the fecal microbiota using 16S rRNA sequence data. The DNA
sequences of each sample were individually aligned and clustered using RDP
web tools Aligner and Complete Linkage Clustering.

Individual cluster files

corresponding to each fecal sample were used to construct Rarefaction curves
and determine the Shannon’s Index.
Statistical

analysis.

To

identify

differences

in

fecal

microbiota

composition induced through dietary treatments (0.0 g, 2.5 g, 5.0 g, and 10.0 g
GOS) in all eighteen subjects, one-way ANOVA tests with repeats were
performed. Samples obtained during the baseline and washout periods were not
included within the statistical analysis. Post hoc pair-wise comparisons were
done using Tukey’s method.

P-values of < 0.05 were considered significant

unless otherwise stated.
In vitro Fermentation of GOS by colonic bacteria. A total of twenty-two
anaerobic bacteria which were mainly of intestinal origin were screened for their
ability to use GOS as a growth substrate. Included were Clostridium butyricum
23588, Clostridium bifermentans 23591, Clostridium difficle 23596, Clostridium
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innoccuum 23601, Clostridium paraputrificum 23600, Clostridium perfringes
23962, Clostridium perfringes 23508, Clostridium ramosum 23617, Clostridium
rumen

23494,

Clostridium

sporogenes

23598,

Clostridium

histolyticum

19401,Enterococcus faecium 2354, Enterococcus faecalis 537, Enterobacter
aerogenes 407, Enterobacter aerogenes 410, and Streptococcus salivarius 3714,
Bacteroides thetaiotaomicron 5482, Bacteroides distasonis V923, Bacteroides
fragilis 43858, Bacteroides uniformis BU1100, Bacteroides fragilis 638, and
Bacteroides ovatus V975.

Bacteria were initially propagated in Brain Heart

Infusion (BHI) or Reinforced Clostridial Agar (RCA), and were transferred (2%)
into a basal medium containing 5 g/L Peptone No 3 (Becton, Dickinson, and
Company), 5.0 g/L Casitone (Becton, Dickinson, and Company), 0.5 g/L LCysteine (Sigma), 40 mL Salt Solution, 10 mL Hemin (Sigma), 900 µL Vitamin
K3 (Sigma), and 1 g/L Yeast Extract (Becton, Dickinson, and Company).

In

addition, cells were also inoculated into basal medium containing either 1%
glucose or 1% GOS.

All cultures were incubated at 37˚C in an anaerobic

chamber (Forma Scientific, Mareitta, Ohio) containing an atmosphere of 85%
Nitrogen, 10% Hydrogen, and 5% Carbon dioxide and assessed for growth by
optical

density

measurement

at

600nm

in

a

Beckman

Model

640

spectrophotometer. Each experiment was replicated in triplicate and the average
optical densities were determined.
RESULTS
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The effect of GOS on the fecal microbial community in human
subjects. A total of 288 fecal samples were sequenced by pyrosequencing, and
2.3 million sequences were obtained, with an average of 8,200 sequences per
sample (after quality control analysis). The mean sequence length was
approximately 450 bp. Subsequent identification of operational taxonomic units
(OTUs) among the samples revealed an average of 2,022 OTUs per subject. To
assess the effect of GOS on diversity of the fecal microbiota during the baseline,
treatment, and washout periods, rarefaction curves for all eighteen subjects were
generated (Figure S1). Rarefaction analyses, however, revealed that
consumption of GOS did not cause significant alterations in the bacterial diversity
of the fecal samples (p < 0.0713).
During the baseline period, the composition of the microbiota among the
eighteen subjects was dominated by the phyla Firmicutes (64%) and
Bacteroidetes (28%). Other phyla detected included Actinobacteria (3%),
Verrucomicrobia (1%), and Proteobacteria (1%). Approximately 3% of the
sequences remained unclassified. At the family level, the predominant groups
were the Lachnospiraceae (31%), Ruminococcaceae (18%), Bacteroidaceae
(12%), and Bifidobacteriaceae (5%). The most common genera included
Bacteroides (12.2%), Fecalibacterium (7.7%), Blautia (7.4%), Ruminococcus
(3.7%), Roseburia (2.2%), Bifidobacterium (1.5%), and Dorea (1.3%).
Sequence proportions determined by pyrosequencing were used to
determine the effect of GOS on the composition of the gastrointestinal microbiota
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among all 18 subjects. The groups that were significantly affected are shown in
Table 1, according to phylum, family, genus (by RDP Classifier), and species (as
OTUs). The control chew (no GOS) had no effect on the fecal microbiota, as the
microbial populations during this period were the same as during the baseline
and washout. In addition, a dose of 2.5 gram of did not induce any detectable
changes within the fecal microbiota. In contrast, consumption of 5.0 g GOS led
to a significant increase (p < 0.05) of bifidobacteria at both the family and genus
level, compared to the control dose. At the species level, the abundance of only
one OTU that accounted for the species , Fecalibacterium prausnitzii, increased
significantly at this dose. A significant decrease in abundance was also
observed for both the family and genus level for Bacteroidaceae (p < 0.01) and
Bacteroides (p <0.01), respectively, at the 5.0 g dose compared to the control.
At the 10.0 g GOS dose, taxonomy-based analysis (using Classifier)
revealed differences in the proportions of several phyla. There was a significant
increase in Actinobacteria compared to the control (p < 0.001), as well as
compared to the 2.5 g dose (p < 0.05). This change was associated with an
increase both in the family Bifidobacteriaceae and in the genus Bifidobacterium.
The BLASTn analysis revealed that eight of the OTUs showed statistically
significant differences as the GOS doses increased, with five of the OTUs being
linked to known bacterial species. A significant increase was observed after the
10.0 g dose with six OTUs that account for Bifidobacterium species (Table 1).
Three of these OTUs account for the described species Bifidobacterium
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adolescentis, B. longum, and B. catenulatum, while three showed <97% identity
to the closest type strain (Table 1, Figure 1). Interestingly, two of OTUs that did
not account to any described Bifidobacterium species (Bifidobacterium spp II (p <
0.05), Bifidobacterium spp III), showed the numerically highest response to GOS
(Table 1).
There were a very small number of bacterial taxa other than bifidobacteria
that were influenced by GOS. Significant decreases were observed only within
the family Bacteroidaceae (p < 0.05) and the genus Bacteroides (p < 0.05) when
compared to the control dose of GOS. The OTU-based approach identified two
additional taxa that differed significantly, including Coprococcus comes (p <
0.05), and Fecalibacterium prausnitzii (p < 0.05), both of which decreased after
10.0 g of GOS when compared to the control and 5.0 g, respectively. However,
a significant increase in Fecalibacterium prausnitzii (p < 0.05) was observed after
a dose of 5.0 g of GOS compared to the control (Table 1). There were also
significant decreases that were observed within two species groups,
Fecalibacterium prausnitzii (p < 0.05) when compared to the 5.0 g dose, and
Coprococcus comes (p < 0.05) when compared to the control dose.
Consumption of GOS induced population shifts that were substantial
but varied between subjects. The consumption of GOS at higher levels, 5.0 g
and especially 10.0 g, resulted in major compositional shifts within the
gastrointestinal microbiota of a subset of subjects. The most substantial
alterations, numerically, were the changes observed in the abundances of the
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genus Bifidobacterium, that increased approximately 10 fold (from 1 - 4% to 18 33%) in four subjects, and an about 5 fold in seven additional subjects. In
contrast, there was a a decrease in the abundance of Bacteroides in 17 subjects
after the 5.0 g GOS dose, with 14 of those subjects having a further decrease
after consumption of 10.0 g of GOS. The findings clearly showed that despite
these substantial overall population shifts, the effect of GOS on the intestinal
composition of subjects was still subject to considerable variation among
individuals (Figure 2). The data revealed that there were some individuals that
were essentially unaffected by GOS consumption, whereas other experienced
several significant changes. The most consistent alteration detected by this
analysisod was the reduction in the Bacteroidetes (at the family, genus, and
species levels), which occurred within all of the subjects at some point after 5.0 g
of GOS was consumed (Figure 2). Other common alterations were the increase
in the Actinobacteria (at the phylum, family, genus, and species levels) which
was observed in sixteen of the eighteen subjects after 5.0 g and seventeen of the
subjects after 10.0 g of GOS.
Temporal dynamics of microbial populations in response to GOS.
Analyses of the community profiles provided insight into how GOS influenced the
population dynamics over the entire 16 week study period. All of the changes
induced by GOS were reversible within one week, and no differences (Student’s
t-test, p > 0.05) could be detected in the proportions of the bacterial groups
between the first washout sample and the baseline sample (Figure 3). The
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temporal patterns of the three main phylum (Actinobacteria, Bacteroidetes, and
Firmicutes) and two of the selected genera (Bifidobacterium and Bacteroides) for
five representative subjects showed that these groups were stable in their
temporal response to GOS. For example, levels of Actinobacteria,
Bacteroidetes, and Firmicutes were remarkably stable in fecal samples at the
baseline and washout periods, and their populations returned to the baseline
level within one to two weeks after GOS consumption was stopped. The same
observations were also made at the genus level for Bifidobacterium and
Bacteroides. These taxa were significantly affected by consumption of GOS, as
population dynamics were very similar throughout, indicating that these bacterial
groups might be specifically targeted
In vitro growth of gastrointestinal microbiota cultures on the
prebiotic GOS. The growth of twenty-two strains of bacteria, most of which
originated from the human intestinal tract, in media containing GOS was
compared with growth in media containing glucose (positive control; data not
shown) or without an additional source of carbohydrate. In general, 6 of the 11
Clostridium strains could utilize GOS (Figure S3A) indicated by a higher final OD
when compared to growth without carbohydrates, and in addition, three of the six
strains of Bacteroides also grew well on GOS. Growth on GOS was not
observed, however, for Enterococcus, Enterobacter, or the species included
within the genus Enterococcus and Streptococcus did not result in significantly
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different high levels of fermentation on GOS, when compared to the control (no
GOS).

DISCUSSION
We recently reported that consumption of GOS induced bifidogenic shifts
in the fecal microbial community of 18 healthy human adults (15). Daily doses of
5.0 g were generally necessary before these effects could be observed either by
cultural methods, DGGE, and qRT-PCR. The results were consistent with
several other studies involving human subjects consuming GOS at similar doses
(7, 8, 16, 58). In addition, we also observed that when the fecal samples from
each subject were analyzed individually, the bifidogenic response to GOS
occurred consistently in only half of the subjects, whereas the others were
consistent “non-responders” (15). However, because of the relatively low
resolution of DGGE and the Bifidobacterium-specific primers used in qRT-PCR,
we were unable to detect other changes in the microbiota that occurred as a
result of GOS consumption. Therefore, all 288 samples (18 subjects at 16
weekly time points) from the previous study were used in pyrosequencing
reactions to obtain individual community profiles. Our findings were entirely
consistent with our previous report, but also revealed important insights
regarding how GOS influences the intestinal microbiota.
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Prebiotics are described, by definition, as being “selectively fermented”
and able to induce changes in the gastrointestinal microbiota that are “specific”
(45). Previous methods have been effective in assessing the effect of GOS
consumption on the stability and diversity of the human intestinal microbiota (15,
39, 52); however, the inability to quantify the prebiotic effect beyond the major
taxa has made it difficult to test this definition and to assess the effect of
prebiotics at greater resolution. Results from high throughput pyrosequencing
has now allowed an in depth analysis of the microbial community as a whole and
has shown for the first time that GOS induces changes that are remarkably
selective. Indeed, the only bacteria that consistently increased in abundance in
response to GOS feeding were bifidobacteria. Moreover, this increase in
bifidobacteria abundance, to greater than 20% in some individuals, was generally
at the expense of only one group of bacteria, namely the genus Bacteroides.
Although abundance of Bifidobacterium increased in some individuals without a
commensurate decrease in Bacteroides (and vice versa), in general,
bifidobacteria increased and bacteroides decreased (Table 1, Figure 2) during
GOS consumption. This data clearly shows that GOS, as a prebiotic, is highly
specific toward the Actinobacteria phylum, in particular bifidobacteria (Figure 1B).
In this study, we observed not only changes at phylum, family, and genus
level, but perhaps more importantly, also at the species level (Figure 2A and B).
The most consistent response, at the 10.0 g treatment, was an increase of
Bifidobacterium adolescentis that was detected in eight out of the eighteen
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subjects. Interestingly, this was the same species that we previously identified
from DGGE analyses and that Tannock et al. (2004) also detected in response to
GOS consumption. Although Bifidobacterium are generally associated with
humans and animals, B. adolescentis, in particular, is common in children and
dominant in adults (4, 5, 6, 40). The abundance of two other Bifidobacterium
species also increased at the 10 g GOS dose, Bifidobacterium longum and
Bifidobacterium catenulatum, as well as three unidentifiable Bifidobacterium spp
(Table 1; Figure 1A and B). This data suggests that while GOS is highly specific
toward the genus Bifidobacterium, the ability to ferment GOS appears to extend
to only a few species.
As we noted previously, the response to GOS consumption is subject to
considerable individual variation (38), an observation confirmed by the
pyrosequencing data. Of the 54 OTUs that were identified in individual subjects,
46 did not reach significance when all of the subjects were included in the
analysis. In addition, none of the taxa that were significantly affected by GOS
showed a response in all eighteen subjects. Of the eight OTUs that were
identified as significant, only two were closely identified with B.adolescentis. Due
to the high percentage of shared sequences, these two OTUs were re-analyzed
with a 98% similarity score, as well as a chimera test. They were subsequently
classified as separate OTUs, confirming that this species was most commonly
increased (seen in eight subjects) with consumption of GOS (Figure 1A).
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The highly individual response to GOS may occur for one of several
possible reasons. First, the presence or absence of specific strains, capable of
metabolizing GOS, would appear to be the major determinant, as few OTUs are
completely conserved among humans (54, 57). Thus, the presence of specific
GOS-metabolizing strains would confer responder status on that individual, other
individuals in which GOS strains are absent would be non-responders. Other
factors could also account for these results, including host specific environmental
constrains that would restrict the ability of the bacterial group to increase in
numbers even if a suitable substrate is provided (38). In addition, host digestive
enzymes may be secreted that affect the amount of GOS that withstands
digestion.
The ability of GOS to support growth of a range of colonic bacteria, as we
observed in this study (Figure S3A), would appear to be inconsistent with the
very definition of a prebiotic. The ability of species of Clostridium, Bacteroides
and Streptococcus to utilize GOS in pure culture, has previously been reported,
as well Rycroft et al. (2001). Clearly, however, the substrate preferences and
competitive forces that exist in the gastrointestinal environment are quite different
from pure monoculture environments. Although the abundance of Actinobacteria
was much lower than Firmicutes or Bacteroides during baseline and control
periods, only the former group was stimulated by GOS, despite the apparent
ability of the latter groups to grow on GOS. Thus, it would appear that a
competitive environment is necessary to demonstrate a prebiotic effect.
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Table 1. Abundance of bacterial taxa that were impacted by GOS consumption in fecal samples of eighteen human
subjects as determined by pyrosequencing of 16S rRNA tags.
Proportion of bacterial taxa expressed in percentage (Mean ± SD)
Phylum
A ctinobacteria

B aseline1

0.0 g 2

2.5 g 2

5.0 g 2

2.52 ± 2.34

2.58 ± 3.59

3.69 ± 4.33

5.39 ± 6.11

Family
B ifidobacteriaceae

1.87 ± 2.28

2.03 ± 3.59

2.99 ± 3.72

5.11 ± 5.77

B acteroidaceae

Genus
Bifidobacterium
Bacteroides

Species (OTUs)
B. adolescentis

10.0 g 2

1.54 ± 1.95

1.68 ± 2.97

2.55 ± 3.25

4.32 ± 5.03

7.19 ± 8.88

*

12.22 ± 7.43 15.03 ± 10.66 13.29 ± 9.24 11.20 ± 9.11

**

*

12.22 ± 7.43 15.03 ± 10.66 13.29 ± 9.24 11.20 ± 9.11

W ashout

**

***§

P value 3

2.09 ± 2.51 < 0.0001

7.36 ± 8.68
1.49 ± 2.36 < 0.0001
***§§
*
11.66 ± 9.22
13.69 ± 8.27 0.003
6.24 ± 7.71

***§§
*

11.66 ± 9.22
*

0.37 ± 0.56

0.34 ± 0.89

0.46 ± 0.86

0.85 ± 1.09

1.03 ± 1.55

Bifidobacterium spp I

0.15 ± 0.36

0.18 ± 0.33

0.25 ± 0.55

0.52 ± 1.13

0.77 ± 1.41

Bifidobacterium spp II

0.46 ± 0.94

0.60 ± 1.53

0.76 ± 1.72

1.41 ± 2.38

2.00 ± 3.45

Bifidobacterium spp. III 0.62 ± 1.21
B. longum
0.09 ± 0.23
B. catenulatum
0.15 ± 0.34

0.78 ± 2.19

0.98 ± 2.02

1.82 ± 3.30

2.50 ± 4.55

0.09 ± 0.23

0.12 ± 0.32

0.22 ± 0.50

0.33 ± 0.85

0.27 ± 0.88

0.56 ± 1.38

0.91 ± 2.08

F. prausnitzii

3.52 ± 2.71

3.21 ± 2.26

3.71 ± 2.67

0.51 ± 1.16
*
4.37 ± 3.67

**

Coprococcus comes

2.90 ± 2.04

2.40 ± 1.75

2.12 ± 1.24

1.99 ± 1.55

3.16 ± 1.82
1.78 ± 1.11

†

Bacteria populations are averages of the two time points of the baseline period and the two time points of the washout
period.
2
Bacteria populations are averages of all three time points of the feeding periods
3 Bacterial populations during the dietary treatments were compared to eachother with repeated measures ANOVA
and Tukey’s post hoc test
Significantly different to 0.0 g: *(p < 0.05), **(p < 0.01), ***(p < 0.001)
Significantly different to 2.5 g: §(p < 0.05), §§(p < 0.01)
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Figure 1. Characterization of the fecal microbiota in eighteen subjects that
consumed increasing doses of GOS by multiplex pyrosequencing of 16S rRNA
tags. A phylogenetic tree that encompasses the phylum (A) Actinobacteria is
shown. The tree contains representative sequences of all OTUs detected to be
impacted by GOS in individual subjects together with sequences of related
entries in the database (which included both type strains of known species and
sequences from molecular studies of human fecal samples). Sequences were
aligned in Muscle 3.6 and the trees were built using the neighbor-joining
algorithm with 1,000 bootstrap replicates in MEGA 4.0. Open black and closed
black symbols were used to label sequences from individual subjects. OTUs that
were not significantly affected in all eighteen subjects were labeled as ‘No
significance.’ The graphs next to the trees show the abundance of OTUs and
bacterial groups that were significantly altered during the dosages (0.0 g, 2.5 g,
5.0 g, and 10.0 g). A graph (B) that incorporates all of the Bifidobacterium
species altered during consumption of GOS, for all eighteen subjects, is also
shown. These graphs show mean proportions of the three individual samples
taken during the treatment periods for each subject. Baseline and washout refer
to samples taken in periods where no GOS was consumed. Repeated measures
ANOVA in combination with a Tukey’s post-hoc test were performed to indentify
differences between treatment groups, and the baseline/washout periods were
not included in the statistic analysis. (*p < 0.05, **p < 0.01, ***p < 0.001).
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***
***
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Figure 2. Bubble plots showing differences in the proportions of bacterial taxa as
a percentage of the whole bacteria population detected during consumption of
5.0 g (A) and 10.0 g (B) when compared to the control period. The size of the
bubbles is representative of the percent difference. Black ovals represent
increases in proportions induced through GOS consumption, and white ovals
represent a decrease.
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Figure 3. Temporal dynamics of the human fecal microbiota in response to the
consumption of increasing doses of GOS shown in five human subjects. Graphs
on the left show proportions of the three main phyla and two genera
(Bifidobacterium and Bacteroides) altered for subjects considered ‘responders’,
which graphs on the right show proportions of the same three main phyla and
two genera altered for subjects considered ‘non-responders’.
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Figure S1. Diversity of species richness of the fecal microbiota in eighteen
human subjects that consumed doses of 0.0 g, 2.5 g, 5.0 g, and 10.0 g of GOS.
Rarefaction curves showing the amount of OTUs in all individual fecal samples
taken from eighteen subjects.
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Figure S2. Characterization of the fecal microbiota in eighteen subjects that
consumed increasing doses of GOS by multiplex pyrosequencing of 16S rRNA
tags. Phylogenetic trees that encompass the phyla (A) Firmicutes and (B)
Bacteroidetes are shown. The trees contain representative sequences of all
OTUs detected to be impacted by GOS in individual subjects together with
sequences of related entries in the database (which included both type strains of
known species and sequences from molecular studies of human fecal samples).
Sequences were aligned in Muscle 3.6 and the trees were built using the
neighbor-joining algorithm with 1,000 bootstrap replicates in MEGA 4.0. Open
black and closed black symbols were used to label sequences from individual
subjects. OTUs that were not significantly affected in all eighteen subjects were
labeled as ‘No significance.’ Arrows to the right of each cluster indicate the
number of subjects that showed statistical significance after ANOVA analysis.
The direction of the arrow indicates either a significant increase (↑) or significant
decrease (↓) for each subject showing significance for that particular OTU
cluster.
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B. Bacteroidetes
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Figure S3. Twenty-two anaerobic bacteria of human gastrointestinal origin were
screened in vitro to determine their ability to utilize GOS. Optical density for each
of the strains is shown (A), with significant differences determined by students Ttest and indicated by (* p < 0.05). Each of the strains used in the study (B) were
obtained from the USDA.
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Chapter 4

Conclusion

138

In this research, we established that consumption of the prebiotic GOS
induced changes on the composition of the human gastrointestinal microbiota.
Evidence for this conclusion was exhibited using both cultural and molecular
methods to enumerate and characterize the shift in selected bacterial
populations. Specifically, selective plating methods were used to enumerate
bifidobacteria, Bacteroides, enterobacteria, Enterococci, lactobacilli, and total
anaerobes. Culture-independent methods included denaturing gradient gel
electrophoresis (DGGE), quantitative real-time PCR (qRT-PCR), and high
throughput multiplex community sequencing of 16S rRNA tags. We
hypothesized that after a particular dosage level of GOS, a bifidogenic response
would occur. Also, we anticipated that GOS would have a community wide affect
outside of the known bifidobacteria population. Described below are the major
findings of this research.
 A dose response relationship necessary to elicit a bifidogenic effect in a
majority of subjects was seen after a 5 g dose of high purity GOS.
 Even when GOS was administered for many weeks and at high doses,
there were still some individuals for whom a bifidogenic response did not
occur; this results supports the concept that some individuals are
responders whereas other are non-responders.
 The population shifts caused by consumption of 10 g of GOS were
numerically substantial, leading to a ten-fold increase in bifidobacteria in

139

four subjects, enriching them to 18-33% off the fecal microbial community,
and a five-fold increase in seven additional subjects.
 The increase in bifidobacteria abundance was generally at the expense of
only one group of bacteria, namely the genus Bacteroides.
 GOS is utilized by a wide variety of bacterial inhabitants of the intestinal
tract when studied in vitro, but is remarkable for its ability to enrich very
specifically for bifidobacteria in vivo.

